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CHAPTER I 
    Introduction 
 
1.1 Introduction 
In the past decades, diabetes mellitus has become a major health problem world wide, 
reaching epidemic proportions in many developing countries including India. World wide 
projections suggest that >220 million people will have diabetes by the year 2020 and 
majority of these (approximately 213 million) will have type-II diabetes. Recently Diabetes 
mellitus has emerged as a leading metabolic disorder. India is the diabetic capital of the 
world, with 41 million people affected with the disease.( Ranjith Unnikrishnan., et al 2007) 
It is the most prevalent disease in the world affecting 25% of population and afflicts 
150 million people and may raise to 300 million by 2025. Diabetes mellitus is considered as 
one of the five leading cause of death in the world. India with largest diabetic population is 
expected to have 57.2 million diabetic patients by the year 2025. The National Urban 
Diabetes study (NUDS) was recently conducted in six major cities covering all regions of the 
country. In each of the cities studied, prevalence of diabetes is higher than 9% ranging from 
9.3%-16.6%. The average diabetic prevalence in urban Indian adults is 12.1%. prevalence of 
diabetes in rural area is 4 to 6 times lower than in the cities.( Azad Khan et al 1995) 
Recently WHO and International Diabetic Federation (IDF) reports show that the 
incidence of diabetes is increasing at an epidemic rate, especially in developing countries, 
probably due to rapidly changing life style, eating habits and environmental conditions. India 
has been projected by WHO as the country with fastest growing population of diabetic 
patients. It is estimated that between 1995-2025 diabetic patients in India will increase by 
195%.( Chatterje, M.N. and Rana Sinde 1995) 
1.2Global Scenario 
The overwhelming burden of the disease continues to be shouldered by low- and 
middle- income countries where four out of five people are living with diabetes. The burden 
of diabetes is reflected not only in the increasing numbers of people with diabetes, but also in 
the growing number of premature deaths due to diabetes. In 2013, approximately half of 
deaths are due to diabetes in adults under the age of 60 and in less-developed regions like 
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sub-Saharan Africa, that proportion climbed to 75%. Globally diabetic population is 
increasing at an alarming rate (Cho et al., 2013). 
1.3 Indian Scenario 
India with its dubious distinction of being called, ―the diabetic capital of the world‖ is 
presently estimated to have over 30 million individuals suffering with this deadly disease. 
The prevalence of diabetes in India is over 12 %. It is estimated that there are 30 million 
diabetics in India today. India is ahead of China and USA, which are in second and third 
place, respectively.  
To certain extent geographical distribution influences the pattern of diabetes 
incidences across India (Kaveeshwar and Cornwall, 2014). The results of a study conducted 
by the Indian Council of Medical Research (ICMR) revealed that the states of Northern India 
((Chandigarh 0.12 million, Jharkhand 0.96 million) had a lower incidence of diabetes unlike 
Maharashtra (9.2 million) and Tamil Nadu (4.8 million) (Anjana et al., 2011). These results 
corroborated with the findings of The National Urban Survey conducted across the 
metropolitan cities of India whose results showed a statistical report of 11.7% diabetes 
incidence in Kolkata (Eastern India), 6.1% in Kashmir Valley (Northern India) (Zargar et al., 
2000), 11.6% in New Delhi (Northern India), and 9.3% in West India (Mumbai) as compared 
to 13.5% in Chennai South India, 16.6% in Hyderabad (south India), and 12.4% in Bangalore 
(South India) (Ramachandran et al., 2001). 
The overburdened healthcare system has difficulty in providing means of glycemic 
control to the millions of patients. This failure today may lead to a future onslaught of 
complications, particularly cardiovascular complications, which further challenge the 
resources of the Indian health-care system 
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1.4TYPES OF DIABETES MELLITUS 
Type 1 Diabetes mellitus (DM) results from the pancreatic failure to produce enough 
insulin. This form was previously referred to as "insulin-dependent diabetes mellitus" 
(IDDM) or "juvenile diabetes". The cause is unknown.
 
 
Type 2 Diabetes mellitus begins with insulin resistance, a condition in which cells fail 
to respond to insulin properly. As the disease progresses lack of insulin also develops. This 
form was previously referred as "non-insulin-dependent diabetes mellitus" or "adult-onset 
diabetes". The primary cause is excessive body weight and lack of exercise.
 
 
Gestational diabetes, is the third main form and occurs when pregnant women without 
a previous history of diabetes develop a high blood sugar level. 
1.5 Signs and Symptoms 
 The classic symptoms of untreated diabetes are weight loss, polyuria  polydipsia 
and polyphagia that may develop rapidly in type 1 diabetes, while they usually develop much 
more slowly and may be subtle or absent in type 2 diabetes. Several other signs and 
symptoms can mark the onset of diabetes, although they are not specific to the disease. In 
addition to the known ones as described above, blurry vision, headache, fatigue, slow healing 
of cuts, and itchy skin, are the other symptoms often seen in diabetic patients. Prolonged high 
blood glucose can cause glucose absorption in the lens of the eye, which leads to changes in 
its shape, resulting in vision changes. A number of skin rashes that can occur in diabetes are 
collectively known as diabetic dermatomes. 
 Prevention and treatment involve a healthy diet, physical exercise and avoiding 
 tobacco. Blood control and proper foot care are also important for people with the disease. 
Type 1 diabetes is managed with insulin injections. Type 2 diabetes is often treated with 
medications with or without insulin. Insulin and some oral medications can cause low blood 
sugar. Weight loss surgery in those with obesity is sometimes an effective measure in people 
with type 2 DM. Gestational diabetes usually resolves after the birth of the baby. As of 
2014, an estimated 387 million people have diabetes worldwide, with type 2 diabetes making 
up about 90% of the cases. This represents 8.3% of the adult population, with equal rates in 
both women and men. From 2012 to 2014, diabetes is estimated to have resulted in 1.5 to 4.9 
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million deaths each year. Diabetes at least doubles a person's risk of death. The number of 
people with diabetes is expected to rise to 592 million by 2035. The global economic cost of 
diabetes in 2014 was estimated to be $612 billion USD. In the United States, diabetes cost 
$245 billion in 2012.( Amy Aronouitz et  al.,2006) 
1.6 Type 2 Diabetes Mellitus 
 Type 2 diabetes mellitus is characterized by insulin resistance, which may be 
combined with relatively reduced insulin secretion. The defective responsiveness of body 
tissues to insulin is believed to involve the insulin receptor. However, the specific defects are 
not known. Diabetes mellitus cases due to a known defect are classified separately. Type 2 
diabetes is the most common type. 
In the early stage of type 2, the predominant abnormality is reduced insulin 
sensitivity. At this stage, hyperglycemia can be reversed by a variety of measures and 
medications that improve insulin sensitivity or reduce glucose production by the liver. Type 2 
diabetes is due primarily to lifestyle factors and genetics. A number of lifestyle factors are 
known to be important for the development of type 2 diabetes, including obesity (defined by 
a body mass index of greater than thirty), lack of physical activity, poor diet, stress, 
and urbanization. Excess body fat is associated with 30% of cases in those of Chinese and 
Japanese descent, 60–80% of cases in those of European and African descent, and 100% of 
Pima Indians and Pacific Islanders. Even those who are not obese often have a high waist–hip 
ratio. Dietary factors also influence the risk of developing type 2 diabetes. Consumption 
of sugar-sweetened drinks in excess is associated with an increased risk. The type of fats in 
the diet is also important, saturated fats and trans fatty acids increase the risk of diabetes 
and polyunsaturated and monounsaturated fat decrease the risk. Eating lots of white rice also 
appears to play a role in increasing the risk. Lack of exercise is believed to cause 7% of 
cases.( Agarwal,2003) 
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1.7 Gestational Diabetes 
 Gestational Diabetes Mellitus (GDM) resembles type 2 diabetes in several respects, 
involving a combination of relatively inadequate insulin secretion and responsiveness. It 
occurs in about 2–10% of all pregnancies and may improve or disappear after 
delivery. However, after pregnancy approximately 5–10% of women with gestational diabetes 
are found to have diabetes mellitus, most commonly type 2.Gestational diabetes is fully 
treatable, but requires careful medical supervision throughout the pregnancy. Management 
may include dietary changes, blood glucose monitoring, and in some cases insulin may be 
required. Though it may be transient, untreated gestational diabetes can damage the health of 
the fetus or mother. Risks to the baby include macrosomia (high birth weight), congenital 
cardiac and central nervous system anomalies, and skeletal muscle malformations. Increased 
fetal insulin may inhibit fetal surfactant production and cause respiratory distress syndrome. 
A high blood bilirubin level may result from red blood cell destruction. In severe cases, 
perinatal death may occur, most commonly as a result of poor placental perfusion due to 
vascular impairment. Labor induction may be indicated with decreased placental function. 
A Caesarean section may be performed if there is marked fetal distress or an increased risk of 
injury associated with macrosomia, such as shoulder dystocia.( Robbins 1994) 
 Mechanism of insulin release in normal pancreatic beta cells — insulin production is 
more or less constant within the beta cells. Its release is triggered by food, chiefly food 
containing absorbable glucose. 
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Insulin is the principal hormone that regulates the uptake of glucose from the blood 
into most cells of the body, especially liver, muscle, and adipose tissue. Therefore, deficiency 
of insulin or the insensitivity of its receptors plays a central role in all forms of diabetes 
mellitus. The body obtains glucose from three main places: the intestinal absorption of food, 
the breakdown of glycogen - the storage form of glucose found in the liver, 
and gluconeogenesis - the generation of glucose from non-carbohydrate substrates in the 
body. Insulin plays a critical role in balancing glucose levels in the body. Insulin can inhibit 
the breakdown of glycogen or the process of gluconeogenesis, it can stimulate the transport 
of glucose into fat and muscle cells, and it can stimulate the storage of glucose in the form of 
glycogen. Insulin is released into the blood by beta cells (β-cells), found in the islets of 
Langerhans in the pancreas, in response to rising levels of blood glucose, typically after 
eating. Insulin is used by about two-thirds of the body's cells to absorb glucose from the 
blood for use as fuel, for conversion to other needed molecules, or for storage. Lower glucose 
levels result in decreased insulin release from the beta cells and in the breakdown of glycogen 
to glucose. This process is mainly controlled by the hormone glucagon, which acts in the 
opposite manner to insulin. 
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 If the amount of insulin available is insufficient, if cells respond poorly to the effects 
of insulin (insulin insensitivity or insulin resistance), or if the insulin itself is defective, then 
glucose will not be absorbed properly by the body cells that require it, and it will not be 
stored appropriately in the liver and muscles. The net effect is persistently high levels of 
blood glucose, poor protein synthesis, and other metabolic derangements, such as acidosis. 
When the glucose concentration in the blood remains high over time, the kidneys will reach a 
threshold of reabsorption, and glucose will be excreted in the urine (glycosuria). This 
increases the osmotic pressure of the urine and inhibits reabsorption of water by the kidney, 
resulting in increased urine production (polyuria) and increased fluid loss. Lost blood volume 
will be replaced osmotically from water held in body cells and other body compartments, 
causing dehydration and increased thirst (polydipsia). 
1.8Diabetic Complications 
The long-standing medical complications of DM include retinopathy, nephropathy, 
peripheral neuropathy (nerve disease), and heart disease/stroke (Leese et al., 1992). 
1.9 Diabetic Retinopathy 
Diabetic retinopathy is characterized by abnormalities of small blood vessels in the 
retina caused by DM. The end result is the weakening or leakage of these blood vessels, and 
subsequent bleeding into the fluid-filled center of the eye (ADA, 2001; Clayman, 1994). 
Diabetic retinopathy is the leading cause of blindness in individuals between 20-74 years of 
age, with approximately 12,000 to 24,000 individuals becoming blind each year. DM is 
responsible for 8% of legal blindness in the United States (ADA, 2001). 
1.10 Diabetic Microangiopathy 
One of the most consistent morphologic features of diabetes is diffused thickening of 
basement membranes (Tisher et al., 1994). The thickening is most evident in the capillaries 
of the skin, skeletal muscles, retina, renal glomeruli and renal medulla, giving rise to the 
characteristic diabetic microangiopathy of these organs. However, it may also be seen in such 
nonvascular structures as renal tubules, Bowman’s capsule, peripheral nerves and placenta. 
The microangiopathy is clearly related to hyperglycemia. A number of biochemical basement 
membrane alterations occur, including increased amounts and, synthesis of collagen type IV 
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and decrease in proteoglycans. The latter can account for the increased glomerular 
permeability characteristic of diabetic nephropathy. 
1.11Diabetic Nephropathy 
Nephropathy (kidney disease) is a common complication of DM. Diabetic 
nephropathy is a progressive disease, and is the leading cause for end-stage renal disease 
(ESRD) (Leese, 1992). Diabetic nephropathy is characterized by damaged and leaky blood 
vessels in the kidneys. Eventually, the entire filtration system becomes destroyed, and the 
kidneys fail to function. This is called end-stage renal disease (ESRD). Approximately 40% 
of ESRD is due to DM complication (ADA, 2001).The prevalence of micro albuminuria and 
macro albuminuria was significantly higher in patients whose diabetes had developed before 
rather than after the age of 20.  
1.12Diabetic Neuropathy 
Peripheral neuropathy occurs when there is damage to the peripheral nerves that lead 
from the brain and spinal cord out to the rest of the body. Symptoms include tingling and 
numbness of the extremities. Unawareness of injury or infection to the extremities, as well as 
muscular atrophy, can result in amputation. Approximately 60-70 % of individuals with DM 
have some form of nerve damage. DM is the most frequent cause of non-traumatic lower 
limb amputations (Leese, 1992), with individuals with DM being 15-40 times at greater risk 
for leg amputation (ADA, 2001). People with DM run a higher risk of developing 
atherosclerosis, along with risks of high blood pressure, heart attack, and stroke (ADA, 2001; 
Leese, 1992). Heart disease is present in 75% of diabetes-related deaths, and individuals with 
DM are 2 to 4 times more likely to suffer a stroke (ADA, 2001). 
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Table:1 Oral Anti-Diabetic Drugs and their Side Effects 
Drugs Side Effects 
Sulfonylureas Hypoglycemia and usually minor 
skin allergy. 
Meglitinides Hypoglycemia and minor  
symptoms are skin rash or itching; 
gastro-intestinal  upset.  
Biguanides The medication may  cause 
swelling and increased weight 
Thiazolidinediones Fluid accumulation becomes a 
serious problem 
Alpha-glucosidase-  Impairment of vital organs like 
liver results in less annoying side 
effects flatulence or diarrhea.  
Dipeptidyl Peptidase-IV 
Inhibitors 
The headache, inflammation of 
nose and throat, joint problem and 
painful extremities 
D-Phenylalanine 
Derivatives 
Has a risk of lowering the blood 
glucose levels  
Short Acting Insulin- GLP-
1 Analogs 
mild & mainly GI tune time  
(nausea in 44%; vomiting 
&diarrohea) 
Amylin Analogs Produces side effects leading to 
impairment in vision speech 
besides being producing nervous 
weakness and palpitations 
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1.13 Need For Alternative Therapy 
 It is often observed that longer administration of existing synthetic oral hypoglycemic 
agents and insulin are prone to influence blood parameters, gastrointestinal conditions leading 
to hypoglycemic change resulting in losing conscience and disturbing the functions of vital 
organs. Besides the agents cannot be used during pregnancy. 
Even though numerous drugs targeted for carbohydrate hydrolysing enzymes  
(pseudosaccharides), release insulin from pancreatic b-cells (sulphonyl urea), glucose 
utilization (biguanides), insulin sensitizers, PPAR gamma agonists (glitazones) are also in 
clinical practice and the rising diabetes market observes a number of changes (Ashok and 
Tiwari, 2002). The glitazones are intended to address the problem of insulin resistance and 
increase insulin action at the cellular level; nevertheless, various drugs are associated with 
liver toxicity (troglitazone), plus mortality due to hepatic failure (Krische et al., 2000; Stern 
et al., 1999) and raising the symptoms and risk factors for heart disease and heart failure 
(rosiglitazone) (Gale et al., 2001). As the long-term effects on the complications of diabetes 
related to drugs are not yet clear, UK Drug and Therapeutic Bulletin warrants that patients 
taking glitazones be monitored for signs of heart failure (Ashok and Tiwari, 2002). 
In spite of greater advancements made in understanding and managing this disease, 
the graph of diabetes-related complications and mortality are rising unabatedly. Traditional 
medicine - basically plants with various active principles; and therapeutic properties have 
been used since time immemorial by physicians and laymen to treat a great variety of human 
diseases including diabetes.  
1.14 Indian System of Medicine 
Every country in this world is having a system of its own traditional medicine. The 
strong tradition of health care practiced and documented for more than 3000 years in India is 
in the form of Siddha, Ayurveda, Unani, and Yoga & Naturopathy systems of medicine. These 
systems have evolved through centuries of usage and have stood the test of time in providing 
holistic health care to the people and are based on a very intimate and well researched 
understanding that biotic and non-biotic components of the environment play a role in 
promoting holistic health care.  
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Among the traditional systems of medicine existing in India Ayurveda and Siddha are 
most popular.  The Siddha system of medicine is the oldest and is derived from the vegetable 
mineral and animal kingdom. Siddha system which has flourished in the South and Ayurveda, 
is prevalent in the North. These practices deal, not merely with the body of man but also with 
the inner soul. The art of medicine is based on truth and as such it is a divine art not to be 
adulterated for the purpose of money.  
1.15Ayurvedic perspectives of Diabetes Mellitus 
Ayurveda mentions there are 20 types of Diabetes Mellitus 10 are born from slesma 
(Kapha) 6 from pitta and 4 from anila (Vata) 
 
Table: 2 Classification of Prameha according to different ayurvedic Acharyas. 
Charaka Sushruta Vagbhata 
Kaphajameha 
Udakameha Udakameha Udakameha 
Ikshuvalikameha Ikshuvalikameha Ikshumeha 
Sandrameha Sandrameha Sandrameha 
Sandraprasadmeha Pishtameha Pishtameha 
Siktameha Siktameha Siktameha 
Shitameha Lavanmeha Shitameha 
Shuklameha Surameha Surameha 
Shukrameha Shukrameha Shukrameha 
Alalmeha Phenameha Lalameha 
Shanaimeha Shanaimeha Shanaimeha 
Pittajameha 
Ksharameha Ksharameha Ksharameha 
Kalameha Amlameha Kalameha 
Nilameha Nilameha Nilameha 
Lohitameha Shonitameha Raktameha 
Manjishthameha Manjishthameha Manjishthameha 
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Haridrameha Haridrameha Haridrameha 
Vatajameha 
Vasameha Vasameha Vasameha 
Majjameha Sarpimeha Majjameha 
Hastimeha Hastimeha Hastimeha 
Hastimeha Kshaudrameha Madhumeha 
 
Ayurveda states 10 kinds of diabetes produced by kapha are curable, 6 kinds produced 
by pitta are controllable but the 4 kinds produced by vatta are incurable. Many herbs such as 
turmeric, ghooseberry are mentioned in the literature to be useful in the management of 
diabetes.  
In the present dissertation Siddha system and Siddha formulations used in the 
management of Diabetes will be focused.   
1.16 Siddha System of Medicine  
Siddha system is one of the oldest systems of medicine in India. The Siddha system of 
medicine has developed on the basis of Saiva siddhanda philosophy and Dravidian culture.  
The word 'Siddha' comes from the root word 'Siddhi' which means 'an object to be attained' or 
'perfection' or 'heavenly bliss'. Siddhi generally refers to the eight supernatural powers 
enumerated as 'anima' and those who have attained them are called 'Siddhars'. 
Medicine means the prevention of physical illness; 
medicine means the prevention of mental illness; 
prevention means to avert illness; 
medicine therefore is the prevention of death. 
This quotation is an interesting definition of medicine by Tirumoolar -one of the 
greatest and earliest Tamil Siddhar. Lot of authors assume that ―The Tamil Siddhars‖ invented 
or developed the Tamil medical system named Siddha medicine. These worshipful Tamil 
siddhars using their divine powers had classified 4,448 diseases and prescribed medicines 
with real therapeutic value in the form of herbs, roots, salts and minerals.  
 
 
13 
 
The Siddha system basically cures the soul and then the body, the same idea is 
referred by Thirumoolar in his writings Thirumandram, 
Udamparr aziyin uyrirr azhivar 
Thidambada Meignanam seravum matter 
Udambaivalarkumubayamarinthe 
Udambaivalarthanuyirvalarthana 
 
In siddha disease is classified based on the Panchabootha theory and Tridosha theory. 
Vadham, Pitham and Kapham are the three humours which are the life constituents of the 
human body.  Still, there is predominant Vadham, below the umbilicus, predominant Pitham 
in the abdomen and thorax region and predominant Kapham in the head and neck region. 
Vadham plays a vital role to assist the body functions. Pitham is responsible for digestion, 
vision, maintenance of body temperature, hunger, thirst taste etc.  Pallor, indigestion, deep 
sleep, sweet taste in the tongue are functions of Kapham. 
In siddha system of medicine, great emphasis is given to herbs by ancient Siddhars; 
that is stressed in the Tamil poem as follows:   
“Veru paru thazhai paru minginikal 
“Mella mella parpam chenduram  paru 
The treatment plan is to regularize the deviated dosha, to strengthen the thathus and to 
balance the distribution of Prana. Siddha aims at bringing the three doshas to equilibrium.  In 
the treatment of a disease first suggestion is to treat with herbs, followed by mineral 
preparations if necessary.  
The, administration of parpam and chenduram, were identified by five properties. 
One is the suvai or the taste, the guna or the character, the veeriya or the potency, the pirivu 
or class and mahimai or action. All these five properties are based on the five elements theory 
that is present in a drug.   
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1.17 Diabetes in Siddha System of Medicine 
Modern terminology Diabetes mellitus is known as Madumegam in Siddha system of 
medicine. Madumegam is popularly known as Neerizhivu as per Siddha system of medicine.  
The term Diabetes Mellitus is recognized as ‘Madhumeha’ in primeval times. Our ancient 
Siddha Physicians have mastered the science of managing this disorder with effective balance 
of ‘dosha’ using some herbs or plant food sources as medicine and following strict dictary 
regimen (Pathyam). Those indigenous foods alone may not be as effective as insulin in 
lowering the blood sugar but the combination therapy seems to equate with the modern 
methods of drug, diet and exercise. The disease according to the Siddha literature is due to 
the vitiation of kapha humour which results in detoriation of seven udalkattukal (saram, 
sennir, oon, enbu, koluppu, moolai, sukkilam) and derangement of 14 vegangal, ten vayus and 
three doshas. 
 
Siddha has been the first to give an elaborate description of this disease, its clinical 
features, patterns and its management by diet, exercise and herbal or herbo mineral drug. 
More emphasis is laid on the prophylactic and curative measures and not merely on 
symptomatic treatment. The Siddha concept of management of Madhumeham (diabetes) is 
still recognized specifically due to its potential, ready availability and lack of toxicity and 
side-effects. 
Siddha medicine advocates the removal of the root cause of the disease which causes 
the onset of diabetes. It is of primary importance. Secondly it is bringing up of three doshas 
and seven thathus in order. Thus, to set right the seven thathus which are thrown out of order 
due to the vitiation, treatment of diabetes is based on maintaining a normal equilibrium of 
doshas and the body with enough energy to function properly.  
1.18 Aetiology (NOI VARUM VAZHI) 
Superficially this disease is the result of mal functioning of pancreas. The ancient works of 
Siddha, attribute this disease to excessive intake of food rich in carbohydrates, fat and non-
vegetarian food, excessive indulgence of sex, worry, tension, laziness and sedentary jobs.  
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1.19 Symptoms (KURIGUNANGAL) 
The principle symptoms of neerizhivu are poly urea, intense thirst (polydypsia) and 
increased appetite (poly phagia), passing urine slightly yellow in color, pain in the external 
genital organs, loss of weight and pale complexion. If the urine is heated, the sweet odour 
will be percepted, white sediments are also observed. Other symptoms are pain all over the 
body, dysponea and excessive sweating with bad odour, giddiness, vomiting, tastelessness 
and sleeplessness.  
The urine may or may not contain sugar. In the former case, it is called Madhumegam 
(Diabetes Mellitus) and in the latter it is known as Athimoothram (Diabetes Insipidus). In the 
case of Diabetes mellitus, the patient’s skin becomes dry and bowels irregular. The patient 
also suffers from acute burning sensation of the body. As the disease becomes chronic, pulse 
becomes feeble; he or she develops pain in the loins and on the sides. The appetite slowly 
decreases. The feet begins to swell, women experience intense itching in genitals and men 
suffer from balanitis. The patients also tend to suffer from cataract, diabetic coma and 
carbuncle.  
1.20 Classification (NOI ENN) 
Twenty varieties of meha disorders have been discussed by Yugimuni, Agasthiar and 
Theraiyar. The Yugi has classified Meganoi on the basis of color, consistency, taste, smell and 
weight etc., Out of the twenty kinds of megam, four are caused by vali, six are caused by 
azhal and the remaining ten are caused by Iyyam. Each author who have dealt mega disorders 
have differently classified them under three doshas and have given names according to his 
concept. But the number, Signs and Symptoms of the classified disorders are almost identical 
in the description of the disease. Classification of Meganoi described in various texts in 
Indian medicine are as follows: 
Yugimuni Vaithiyachinthamani 800  
Varieties under Vatha 
1) Nei mana neer 
2) Pasumana neer 
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3) Oon mana neer 
4) Seel neer 
Varieties under Pittha 
1) Yani koluppumanna neer 
2) Kattralai manna neer 
3) Sunna manna neer 
4) Enippu megam 
5) Palingu neer 
6) Myatkuruthi neer 
Varieties under Kabha 
1) Vasa neer 
2) Theli neer 
3) Moolaiurukku neer 
4) Ela neer 
5) Kal neer 
6) Sukkila neer 
7) Then neer 
8) Upppu neer 
9) Kalu neer 
10) Eraichi neer 
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1.21 Complications (AVATHTHAIKAL) 
The onset of the following sufferings will follow gradually if the disease is not controlled 
or untreated. 
1. Obesity and inflammation in the urinary tract. 
2. Frequent micturition, diminution of semen’s density and loss of complexion. 
3. Dryness in tongue and flatulent abdomen. 
4. Severe thirst and abnormality, delirium. 
5. Increased quantity of urine and loss of semen. 
6. Difficulty in breathing and sleeplessness. 
7. Vomiting sensation, tastelessness and general weakness. 
8. Formation of abscess or carbuncles. 
9. Irregularities in daily habit, bed ridden and bed sores and uncontrolled motion. 
10. Secondary disease like TB or some other complications develop and finally lead to 
death. 
 
1.22 Diagnosis (NOI KANIPPU) 
According to the Siddha system, diagnosis of any disease is being done through eight 
fold examination (Naa, Niram, Mozhi, Vizhi, Sparisam, Malam, Moothram and Nadi) and 
confirmation through interrogation.  
Naa (Tongue): It remains dry and at times black. 
Niram (Colour): It is different from the original complexion and dryness on the skin. 
Mozhi (Speech): Due to increase of Azhal, the patient is likely to suffer from giddiness and 
hence, there is bound to be diffculty in speech. 
Vizhi (Eye): Dullness in sight and cataract of the eye is observed. 
Malam (Motion): When vali is in high proportion there is constipation. With the increase of 
Azhal there exists diarrohea and increased Iyyam in white, milky motion. 
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Moothiram (Urine): When Iyyam is in excess, urine is  whitish, foamy and appears to have 
sediments. When Azhal increases, it is yellow and sweet enough to attract flies. With the 
increased vali, it resemble ghee with sweet taste. 
Nadi (Pulse): The most important parameter of diagnosis is Nadi. In the developed stage of 
this disease, the Vali, azhal, Iyyam nadi will be feeble. Diabetes is diagnosed with the 
enhanced speed of Azhal nadi.  
1.23 Methods of urine examination: Neerkuri and Neikuri 
Collection of urine 
 Prior to the day of urine examination, the patient should take a balanced diet and rest.  
The first urine is collected in a glass container. 
The colour of urine is noted and a drop of gingelly oil is added to the container and 
the tendency of spread is noted within 1 ½ hour.  
 
 
Neikuri 
A drop of gingelly oil is added in to a wide vessel containing the urine to be tested and 
kept under the sunlight.  The variations of 3 uyir thathu in disease can be diagnosed by the 
behavior of gingelly oil on the surface of urine. 
By the careful examination of the urine with gingelly oil, the physicians can know 
whether the disease is curable or not.  For this purpose, siddhars explained various spreading 
tendencies of oil on urine surface to define the prognosis of disease. 
1.24 Humoural Pathology (MUKKUTRA VERUPADUGAL) 
As referred earlier, disease is always due to the imbalance in the ratio of Vali, Azhal 
and Iyyam. This imbalance affects the Keelnokunkal, seven Udalkattukal and slowly affects 
the appetite. An imbalance in Iyyam does imply an imbalance in the other two Kuttrams too, 
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and also contribute destruction of the system. But all the types of diabetes if left untreated at 
the initial stages will develop in to Diabetes mellitus which is incurable. As per textual 
reference, on examination of pulse (nadi) it could be observed that vitiated Kapha  humour 
joined with vatha humour and pittha humour, combined together contribute further 
destruction of the system. 
1.25 Management of Diabetes by Siddha System of Medicine 
 The need of the hour is to identify and develop innovative plant based 
therapies to combat diabetes, and provide evidence – based plant medicine, and prove the 
advantages of these medicines over the existing therapies. At present globally there is 
resurgence in the usage of plant-based medicines used in traditional systems such as Siddha 
and WHO also recommends the same because of its holistic approach with maximum 
therapeutic potency and minimum side effects. Unfortunately, despite the apparent supremacy 
in terms of multiple therapeutic efficacies of herbal based medicines, well- organized, 
rigorous clinical trial evidences are not adequately available. Considering these, it is 
necessary to provide an alternative solution to counter the diabetic plague through indigenous 
herbal resources used by Siddha practitioners.  
Hence, based on the extensive review of Siddha literature attempts have been made in 
the present work to evaluate scientifically an anti-diabetic Siddha plant drug Nilavembu 
Kudineer. The present study is focused on studying the effect of Nilavembu Kudineer in 
Streptozotocin (STZ) induced diabetic rats and also to assess its clinical efficacy in Type 2 
diabetes mellitus patients. Besides the selected Siddha herbal formulation is also studied from 
chemical and botanical standardization point of view in order to contribute to the suffering 
diabetic population a quality standard anti diabetic Siddha herbal drug. 
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CHAPTER II 
REVIEW OF LITERATURE 
2.1 Medicinal Plants and Diabetes 
In recent years, evidence of cases of "insulin resistance" and the occurrence of side 
effects due to prolonged administration of conventional drugs have triggered the search for 
safe and effective alternatives. Several plant extracts and isolated phytochemicals have been 
evaluated for anti-diabetic activity with a view to identify alternative treatment strategies for 
diabetes. It has been observed that certain resistant cases of diabetes that do not respond well 
to conventional drugs often respond well to supplementation with natural remedies 
(Campbell et al.,1997). 
India has one of world’s richest medicinal plant heritages. The wealth is not only in 
terms of the number of unique species (6160) documented thus far for their medicinal use but 
also in terms of the tremendous depth of traditional knowledge about their uses in human & 
livestock health and also in agriculture. Over 4786 ecosystem specific species of plants are 
used by ethnic communities for human and veterinary health care, across the various 
ecosystems from Ladakh in the trans-Himalayas to the southern coastal tip of Kanyakumari 
and from the deserts of Rajasthan and Kachch to the hills of the Northeast. Codified medical 
systems of Ayurveda, Siddha and Unani have enumerated around 2400 unique species of 
plants that are fully documented in terms of their biological properties, actions and drug 
formulations for a wide range of health conditions (Dharsansankar, 2006) 
In recent years, the popularity of complementary medicine has increased. It is 
observed that dietary measures and traditional plant therapies as prescribed in Ayurvedic and 
other indigenous systems of medicine have been used by the majority of the population. 
Surveys conducted in Australia and US indicate that almost 48.5 and 34% of respondents had 
used at least one form of unconventional therapy including herbal medicine (Eisenberg et 
al.,1993; Maclennan et al.,1996). 
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2.2 Reported Anti-Diabetic Plants and their mechanism  
In the present dissertation with a view to develop a human friendly anti diabetic 
herbal drug, a survey was conducted on herbs and herbal formulation used in the 
management of diabetes. From the review it is noted that many herbs are enriched with anti 
diabetic potentials and their mechanism of anti diabetic action is also evaluated by various 
researchers. (Table.1)  
Table: 3 Reported anti diabetic plants with the mechanism of anti diabetic action   
Sl. No Botanical Name Mechanism of action References 
1 Annona squamosa L. Hypoglycemic and 
antioxidant 
Kaleem et al., 
(2006) 
2 Artemisia pallens Wall. ex. Dc. Anti-hyperglycemic and 
hypolipidemic effect 
Subramanian et 
al., (1996) 
3 Azadirachta indica A. Juss. Blocks the inhibitory 
effect of Serotonin and 
epinephrine on insulin 
secretion mediated by 
glucose. 
Biswas et al., 
(2002) 
4 Beta vulgaris L. Initiates insulin release 
from pancreatic beta cells 
Yoshikawa et 
al.,(1996) 
5 Boerhavia diffusa L. Reduces insulin 
resistance 
Pari and 
Satheesh (2004) 
6 Bombax ceiba L. Hypoglycemic and 
hypolipidemic effect 
Saleem et 
al.,(1999) 
7 Caesalpinia bonducella (L.) 
Fleming 
Antioxidant and anti-
hyperglycemic effect 
Chakrabarti et 
al., (2005) 
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8 Camellia sinensis (L.) O. Kuntze Antihyperglycemic and 
antioxidant effect 
Gomes et al., 
(1995) 
9 Capparis decidua (Forsk.) Edgew. Hypoglycemic, 
hypolipidemic, inhibit 
alpha amylase activity, 
and antioxidant effect. 
Altered level of insulin 
receptor and GLUT-4 
mRNA in skeletal muscle 
Agarwal and 
Chauhan (1988) 
10 Catharanthu sroseus(L.) G. Don. Stimulates insulin release 
from islets of 
Langerhans. 
Marles and 
Farenworth 
(1995) 
11 Croton klozhians L. Concentration depent 
increase in insulin 
secretion in MIN6 cells 
and improve lipid 
parameters in diabetic 
rats 
Govidarajan et 
al.,(2008) 
12 Cuminum cyminum L. Inhibits aldose reductase 
and alpha glucosidase 
activity in experimental 
animals 
Lee (2005) 
13 Emblica officinalis Gaertn. Acute induction of 
insulin release from Beta 
cells of islet of 
Langerhans, 
antihyperlipidemic, 
hypoglycemic and 
Jose and Kuttan 
(1995) 
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antioxidant effect 
14 Eugenia uniflora L. Stimulates insulin release 
from islets of Langerhans 
Arai et al.,(1999) 
15 Enicostemma littorale Blume Hypoglycemic and 
antihyperglycemic effect 
Maroo et al., 
(2003) 
16 Gymnema sylvestre R.Br. Hypoglycemic effect Preuss et 
al.,(1998) 
17 Hibiscus rosa-sinensis L. Anti-hyperglycemic 
effect 
Sachadeva and 
Khemani (1999) 
18 Ipomoea batatas (L.) Lam. Hypoglycemic and 
hypocholesterolemic 
effect 
Kusano and 
Abe (2000) 
19 Momordica cymbalaria Hook. f. Hypoglycemic and 
antioxidant effect 
Rao et al.,(1999) 
20 Musa sapientum L. Anti-inflammatory effect Pari and 
Umamahaswari 
(2000) 
21 Phaseolus vulgaris L. Initiates insulin release 
from pancreatic beta cells 
Tormo et 
al.,(2004) 
22 Psidium guajava L. Inhibits alpha 
glucosidase activity 
Wang et al., 
(2007) 
23 Pterocarpus marsupium Roxb. Stimulates insulin release 
from isolated beta islets 
Ahmed et 
al.,(1991) 
24 Punica granatum L. Reduces insulin 
resistance and Enhancing 
sensitivity by insulin 
Huang et 
al.,(2005) 
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receptor. 
25 Scoparia dulcis L. Hypoglycemic, increases 
glycogenesis and 
decreases 
gluconeogenesis and 
glycogenolysis 
Pari and Latha 
(2005) 
26 Stevia rebaudiana (Bertoni) 
Bertoni 
Glucose lowering activity 
by hepatic 
gluconeogenesis 
Ferreria et 
al.,(2006) 
27 Syzygium alternifolium Walp. Hypoglycemic, 
hypolipidemic, inhibit 
alpha amylase activity, 
antioxidant. Altered level 
of insulin receptor and 
GLUT-4 mRNA in 
skeletal muscle 
Rao and Rao 
(2001) 
28 Tinospora crispa (L.) Hook. f. 
&Thoms 
Insulin-secretagogue 
activity, 
antihyperlipidemic, 
hypoglycemic, 
antioxidant effect 
Noor and 
Ashcroft (1998) 
29 Vaccinium angustifolium Aiton Enhances the uptake of 
glucose in differentiated 
C2C12 muscle cells and 
3T3-l1 adipocytes by 
insulin like and glitazone 
activity 
Louis et 
al.,(2006) 
30 Withania somnifera Dunal. Hypoglycemic and Adallu and 
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antihyperglycemic effect. Radhika (2000) 
31 Cajanus cajan (L) Millsp. Increases insulin  
secretion by pancreatic β 
cells 
Ezikeet 
al.,(2010) 
32 Citrullus colocynthis (L.) Schrad. Stimulates residual 
pancreatic 
mechanism,increases 
peripheral uptake and 
utilizeation of glucose 
Agarwal et 
al.,(2012) 
33 Mangifera indica L. Enhances insulin induced 
glucose uptake through 
translocation of the 
glucose transporter 
 
Sangeetha et 
al.,(2010) 
34 Curcuma longa L. Regulate two or more 
pathways (regulation of 
insulin resistance and β-
cell function) 
Lekshmi et 
al.,(2012) 
35 Carica. papaya. L Regulate β-cell function Sasidharan et 
al.,(2011) 
36 Laminaria japonica J.E Regulate glucose 
absorption in the guts 
Akar et 
al.,(2011) 
37 Zingiber officinale Roscoe Regulate two or more 
pathways (islet cell 
protection and increased 
insulin receptor 
signaling) 
Chakraborty et 
al.,(2012) 
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38 Cinnamomum zeylanicum Blume Regulate insulin 
resistance 
Li et al., (2012) 
39 Trigonella foenum-graecum L. Reduces insulin 
resistance  
Uemura et 
al.,(2010) 
 
2.3 Herbal molecules with anti diabetic potentials: 
There are more than thousands of plant species being used in the treatment of 
Diabetes worldwide. Natural phytochemicals isolated from these plant sources may be 
feasible alternative for treating diabetes. Galegine isolated from Galega officinalis L. showed 
hypoglycaemic and insulin-sensitizing potential (Whitters, 2001). Bellififolin from Swertia 
punicea Hemsl. showed improved insulin sensitivity due to increased expression of key 
proteins such as insulin receptor (IR), insulin receptor substrate (IRS-1) and 
phosphatidylinositol-3-kinase (Tian et al., 2010).  
Rutin, isoquercetin, quercetin, moracin-D, C, N, Norartocarpetin, Chalcomoracin and 
Euchrenone isolated from Morus alba L.showed antidiabetic potential by inhibiting alpha-
glucosidase (Katsubeet al.,2006). Curcumin from Curcuma longa L. revealed activation of 
peroxisome proliferator-activated receptor-gamma (PARP-gamma) (Kuroda et al. 2005). 
Davidigenin, Sakuranetin, 2,4,-Dihydroxy-4-methoxydihydrochalcone, 4,5-di-O-
caffeoylquinic acid, O-caffeonylquinic acid, 6-demethoxycapillarisin from Artemisia 
dracunculus improved insulin sensitivity by IR signaling and inhibition of aldose reductase 
(Wang et al.,2011).  
p-Hydroxybenzoic acid, Chlorogenic acid, Vanillic acid, p-Coumaric acid, Ferulic 
acid, Epicatechin, Catechin, Apigenin, Amentoflavone, Proanthocyanidin, from Nigella 
species inhibits the intestinal absorption of glucose (Meddah et al., 2009). Caffeic acid and 
p-Coumaric acid from Ocimum sanctum L. showed alpha-amylase inhibition activity 
(Wongsaet al. 2012). Salacinol, Kotalanol, De-O-sulfated salacinol, De-O-sulfated 
Kotalanol, Ponkolanol and Salaprinol from Salacia reticulata Wight. exhibited anti-diabetic 
effect through inhibition of alpha-glucosidase (Muraoka et al. 2008).  
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Piperine, pipernonaline and dehydropipernonaline from Piper retrofractum Vahl. 
revealed antidiabetic effect by activating of proteins from the peroxisome proliferator-
activated receptors (Kimm et al., 2011). Proanthocyanidin from Pinus pinaster Aiton. had 
alpha glucosidase inhibitory effect (Bedekar et al., 2010), Petunidin and Myricetin from Vitis 
vinifera L. possess anti-glycation activity (Gharibet al., 2013). Kaempferol-3, 
neohesperidoside isolated from leaves of Bauhinia forficata Link. exhibited significant 
hypoglycemic effect (De Sousa et al.,2004). Isorhamnetin from Hippophae rhamnoides L. 
showed anti-diabetic activity by inhibiting glyconeogenesis (Cao et al., 2003). 
Phytoestrogens from Trigonella foenum-graecum L. inhibited the diffusion or transport of 
glucose independent of hormonal mechanism (Puri, 1999).    
2.4 Siddha System of Medicine 
 Siddha system of medicine is one of the ancient system developed along the banks of 
Tamirabarani in the southern peninsular India. About 8,000 herbal remedies have been 
codified in Siddha literature for treating various diseases. The Agathiyargunavagadam (5000 
BC) has recorded 67 medicinal plants, Pathnenkilkanukkunoolgal such as Sirupanjamoolam, 
Elathy mentioned 81 species, Atharvaveda (4500-2500 BC) narrates 290 species, 
Patharthagunavilakkam and Ayurvedic literature such as Sushrut Samhita (200 BC) have 
described properties and uses of nearly 1100 and 1270 species. These drugs are still used in 
the classical formulations of the Siddha system of medicine. Unfortunately, much of the 
ancient knowledge and many valuable plants are lost at an alarming rate. Number of herbs 
have been long known to possess hypoglycaemic action in both experimental animals and 
humans. Siddha and Ayurveda, are pioneering systems to give a detailed description on the 
clinical features and management of Madhumeha (Diabetes Mellitus). Efforts are being made 
to establish their efficacy in controlling diabetes and its various complications that often 
result in increased morbidity and mortality. 
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2.5 Siddha formulations used in the management of diabetes 
Aavaraiyathichurnam has very good hypoglycaemic effects through enhancing the 
peripheral utilization of glucose, normalizing the hepatic glycolysis and gluconeogenesis, 
which were proved by clinical studies (Anbu and Velpandian, 2012). Efficacy of 
Arugankattai paste on diabetic neuropathy symptoms like burning sensation was notified by 
Rajeev and Sewwandi (2013).     
Sadagopan et al., (2014) suggested Madumega Choornam as beneficial for the 
treatment of type 2 diabetes. Kabilan et al., (2013) studied effect of Madumega karpam in 
the glucose level in alloxan induced albino mice. Anbu et al., (2012) confirmed the use of 
Palingu Abraga Parpam for the treatment of Type II diabetes mellitus in a 3 months clinical 
study.  
Yoganandam et al., (2014) reviewed the Siddha kudineer formulation 
―AavaraiKudineer‖ and found it to be suitable for treating diabetes. Neerizhivu choornam, 
which consists of seven herbal ingredients, was scientifically proved to control the blood 
sugar level (Manavalanand and Gopal, 2014). Sathishet al., (2012) revealed α-glucosidase 
inhibitory effect of Siddha formulation Abraga chendhooram. As many siddha formulations 
are proven scientifically for their anti diabetic action, in the present work a common siddha 
formulation on Nilavembu Kudineer is selected and studied from standardization and 
validation point of view as no attempts were made on its anti diabetic potentials. 
2.6 Literature review on therapeutic potentials of Nilavembu Kudineer 
In the management of diabetes Saravana et al., (2015) focused on statistical 
optimization of Nilavembu Kudineer using Response Surface Methodology (RSM) and its 
antibacterial activity. The combined interactive effect of different variables on Nilavembu 
Kudineer production was studied by RSM. The efficiency of the antibacterial compound was 
tested against clinical isolate such as Salmonella typhi. The variables are Andrographis 
paniculata (Burm.f.) Wall., Piper nigrum L., Plectranthus vettiveroides (Jacob), Zingiber 
officinale Roscoe, Santalum album L. Cyperus rotundus L, Hedyotis corymbosa L,  
Trichosanthes cucumerina L, and Vetiveria zizanioides (L). This study suggested that RSM 
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mediated optimization can be a good method for the enhancement of antimicrobial activity of 
Nilavembu Kudineer.  
Ali et al., (2013) attempted to develop a method to determine the chemical fingerprint 
of andrographolide present in Andrographis paniculata (Burm.f.) Wall., (AP) (Acanthaceae) 
and Nilavembu Kudineer churnam (NVK), a siddha poly herbal formulation. The analysis 
showed that andrographolide concentration was 2.68% in AP and 0.82% in NVK in the 50% 
methanol extract. As there is no scientific evidence for the anti diabetic activity of Nilavembu 
Kundineer in the present dissertation both pre clinical and clinical attempts were made to 
establish the anti diabetic efficacy of the selected Siddha formulation. 
 
2.7Review on anti diabetic efficacy of ingredients of Nilavembu Kudineer 
Ingredients of Nilavembu Kudineer were also assessed individually for their anti 
diabetic potential. Polyphenol extracts of Ginger (Zingiber officinale Roscoe) (Kazeem et al 
2015) were studied for their ameliorating effects on pancreas and in altering renal 
derangements in streptozotocin-induced diabetic rats similarly Piper nigrum L. was also 
evaluated for its hypoglycemic potentials (Onyesife et al.,2014).    
 
Mollugo cerviana L. species were also evaluated for their anti diabetic activity 
(Gopalakrishnan et al 2010 and R. Valarmathi et al 2015) 
 
Similarly Vetiveria zizanioides L. (Karan etal 2013)  Andrographis paniculata, 
(Premanath et al 2015) Plectranthus vettiveroides, (Gopalakrishnan et al 2014) Santalum 
album L, (Kulkarni et al 2012) Trichosanthes cucumerina L, (Kirana et al 2008) and 
Cyperus rotundus L (Raut  et al 2006) were also evaluated scientifically for their anti 
diabetic potentials.  
 
 
 
 
 
 
30 
 
Chapter III 
AIM AND OBJECTIVES 
 
3.1 Aim 
 To establish safety and anti- diabetic efficacy of Siddha formulation Nilavembu 
Kudineer (NVK) and contribute to suffering diabetic population.  
3.2 Objectives   
 To determine botanical and chemical standards for the selected formulations  
 To perform the Acute oral toxicity study of Nilavembu Kudineer in albino Wistar 
rats to establish the safety. 
 To evaluate anti- diabetic activity of Nilavembu Kudineer in Streptozotocin 
induced diabetic rats so as to provide scientific evidences in support of anti 
diabetic claim of the selected Siddha formulation (NVK).  
 To assess Type 2 diabetes mellitus in human subjects using Clinical Siddha 
Diagnostic and Morden parameters. 
 To assess the clinical efficacy of Nilavembu Kudineer in proven Type 2 diabetes   
mellitus human subjects. 
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CHAPTER IV 
Work Plan 
4.1 Standardization studies  
 Identification & authentication of ingredient 
 Preparation of the formulation 
 Botanical and chemical standardization studies 
4.2 Pre-clinical studies 
 IAEC Clearance at SASTRA 
 Acute Toxicity and Anti Diabetic activity 
 Histopathological Evaluation studies  
 Data analysis 
4.3 Clinical studies 
 Ethical Clearance 
 Permission from Study centre NIS 
 Informed Consent forms collection 
 Pilot study 
 Clinical assessment 
 Data analysis and compilation of all research work  
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CHAPTER V 
Materials and Methods 
5 .1.1 Materials and Methods 
 The formulation Nilavembu Kudineer (NVK) was selected from the Siddha classical 
text Siddha vadithyathiratu Various publications depict that each ingredient of Nilavembu 
Kudineer is anti- diabetic and is also proved scientifically for their anti diabetic properties. In 
the present work synergistic anti diabetic efficacy of the Nilavembu Kudineer is evaluated 
through pre clinical and clinical studies. Standards as per the Siddha pharmacopoeia is also 
determined for this formulation to assure the quality of the medicine.  
5.1.2 Drug  collection, identification and authentication 
Selected Siddha drug Nilavembu Kudineer was purchased from authorized IMCOPS 
dealer at Trichy. This drug was manufactured by The Indian Medical Practioners Co-
operative Pharmacy and Stores Ltd, Thiruvanmiyur, Chennai. The commercially procured 
formulation was subjected to various studies for evaluating the anti-diabetic efficacy and for 
the determination of standards in par with modern medicine which is essential for the 
international recognition and global acceptance of this anti-diabetic Siddha drug.  
Preparation of the study drug 
 The study drug was prepared as per standard protocol following the guidelines of the 
Drugs and Cosmetics act 1947.  
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Table:4 Ingredients 
S. No. Ingredients Botanical name Part used Quantity 
1 Nilavembu Andrographis paniculata Burm. f leaves 8.75gms 
2 Vilamichamver Plectranthus vettiveroides Jacob Root 8.75gms 
3 Santhanam Santalum album L. Wood 8.75gms 
4 Peipudal Trichosanthes cucumerina L. Whole plant 8.75gms 
5 Koraikizhangu Cyperus rotundus L. Root 8.75gms 
6 Chukku Zingiber officinale Roscoe Root 8.75gms 
7 Milagu Piper nigrum L. Fruit seed 8.75gms 
8 Parpatakam Mollugo cerviana L. Ser Whole plant 8.75gms 
9 Vettiver Vetiveria zizanioides L. Root 8.75gms 
 
5.2 Method of preparation 
The above purified ingredients are dried and made of aqueous decoction. 
Dosage 30- 60ml once a day.(Oral) 
Duration 45 days 
5.2.1 Preparation of aqueous extract 
 Plant materials were wasted thoroughly with water and cut into small pieces, 
shade dried coarsely powdered and extracted with water. 200 g of plant material was soaked 
in water (2 L) and heated at 80°C for 1 h. The crude extract was filtered using Whatman 
paper and evaporated in vacuo at 60°C using a rotary evaporator.  
  
 
 
34 
 
Ingredients of Nilavembu kudineer 
 
 
 
 
 
 
 
 
 
 
(A).  Andrographis paniculata Burm. f. Leaves & stem (Nilavembu) 
 
   
 
 
 
 
 
 
 
 
 
(B). Plectranthus vettiveroides Jacob. Root (Vilamichamver) 
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(C). Santalum album L. Wood (santhanam) 
 
 
 
 
 
                                    
 
                               
 
 
 
 
                  (D). Trichosanthes cucumerina L. Whole plant (Peipudal) 
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                         (E). Cyperus rotundus L.  Rhizome (Koraikizhangu) 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                     
                     (F). Zingiber officinale Roscoe Rhizome (Chukku) 
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                                    (G). Piper nigrum L.  Fruit (Milagu) 
  
 
 
  
 
 
                                    
 
 
 
 
                                      
                                       
              (H). Mollugo cerviana (L.) Ser. Whole plant (Parpatakam) 
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                                (I). Vetiveria zizanioides L. Root (Vettiver) 
 
 
 
 
 
 
 
 
 
 
(J). Nilavembu powder (Raw material for kudineer)        (K). Nilavembu kudineer 
 
Color: Greenish brown 
Taste: Bitter  
Odor: Slightly aromatic 
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5.3 Botanical Characterization 
5.3.1Organoleptic evaluation 
 Organoleptic evaluation is carried out as per Ayurvedic Pharmacopoeial procedures 
(2004). Standards were evaluated and tabulated. 
5.3.2 Microscopic studies 
Powder Microscopy  
Powder microscopy helps to visualise crystals, trichomes, leaf epidermal cells and 
parenchyma cells.  
A pinch of powdered material was placed on a microscopic slide.  A small amount of 
chloral hydrate and few drops water added. The slide was warmed over a water bath for few 
minutes. The samples treated with chloral hydrate mounted with 30% glycerol and observed 
under microscope.  
Slides prepared  using the test drug were observed under microscope (Zeiss, Scope A-
1, Germany) and microscopic images were captured using CC camera (JENOPTIK, 
Germany) and ProRes C5 software.  
 
5.3.4Histochemical Studies  
Test for Lignin 
A pinch of the powdered plant material was placed on a microscopic slide and stained 
with 1% solution of phloroglucinol in ethanol for 1- 2 mins.  The phloroglucinol drained and 
few drops of conc. HCl added. The excess acid also drained off and few drops of 30% 
glycerol added and then treated powder was mounted and observed under microscope.  Pink 
to cherry red in colour observed indicates the presence of lignin in the plant. 
 
Test for Starch  
A pinch of the powdered plant material was placed on a microscopic slide and stained 
with iodine in potassium iodide solution. Cover glass placed over it and observed under the 
microscope. Starch grains will stain dark blue to dark purple in colour. 
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Test for fats and fatty oil 
A pinch of powdered material placed on a microscopic slide and stained with 2-3 
drops sudan red and allowed to stand for few minutes and observed under microscope.  The 
development of orange red to red in colour indicates the presence of fats, fatty oils, volatile 
oil and resins. The slides were irrigated with   ethanol (750/L) and heated gently. Colour 
obtained due to the presence of volatile oils and resins get dissolved in ethanol. The presence 
of fats and fattly oils were confirmed by the intact orange red to red colour.   
 
Test for calcium Carbonate crystals 
A small quantity of powdered plant material placed on a microscopic slide and treated 
with few drops of acetic acid (60g/L) or hydrochloric acid (70g/L) solution. Dissolving of 
crystals with effervescence indicates the presence of calcium carbonate crystal. 
 
Test for calcium oxalate crystals 
A small quantity of powdered plant material was placed on a microscopic slide and 
treated with few drops of acetic acid (60g/L) or hydrochloric acid (70g/L) solution.   
Crystals of calcium oxalate are insoluble in acetic acid solution, but soluble in hydrochloric 
acid solution without effervescence.  
5.4  Chemical standardization studies 
 5.4.1Tests for identity, purity and strength (Ayurvedic Pharmacopoeia of India, 2004) 
5.4.2 Determination of foreign matter 
Drug sample (100 g) was weighed and spread out in a thin layer (Ayurvedic 
Pharmacopoeia of India, 2004). The foreign matter was detected by inspection with the 
unaided eye or by the use of a lens (6 x). It was separated and weighed and the percentage 
was calculated. 
5.4.3 Determination of total ash 
About 2 g of the powdered drug was weighed in a silica dish at a temperature not 
exceeding 450ºC until free from carbon, cool and weigh (Ayurvedic Pharmacopoeia of India, 
2004). The charred mass was extracted with hot water, the residue was collected in an ashless 
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filter paper, and then the residue was incinerated. The filtrate was evaporated to dryness, and 
ignited at a temperature not exceeding 450ºC. The percentage of ash was calculated with 
reference to the air-dried drug. 
5.4.4 Determination of acid insoluble ash (Ayurvedic Pharmacopoeia of India, 2004) 
The ash obtained from total ash was boiled for 5 minutes with 25 ml of dilute 
hydrochloric acid. The insoluble matter was collected in an ashless filter paper, washed with 
hot water and ignited to constant weight. The percentage of acid-insoluble ash was calculated 
with reference to the air dried drug 
5.4.5 Preliminary phytochemical screening of plant extracts  
 Suitable quantity of Nilavembu Kudineer powder were subsequently extracted and 
phytochemical test were conducted as per methods of Harbone (1973).  
5.5 Estimation of alkaloids (Harbone, 1973) 
  About 2 grams of the powdered sample was mixed with l g of calcium hydroxide and 
5 ml of water into a smooth paste and was set aside for five minutes. It was then evaporated 
to dryness in a porcelain dish on a water bath. To this 200 ml of chloroform was added, 
mixed well and refluxed for half an hour on a water bath. Then it was filtered and the 
chloroform was evaporated. To this 5 ml of dilute hydrochloric acid was added followed by 2 
ml of each of the following reagents.  
(i) Mayer’s reagent  
(ii) Dragendorff’s reagent  
(iii) Hager’s reagent  
(iv) Wagner’s reagent  
Observations were recorded.  
5.5.1 Estimation of mucilage 
10 ml of concentrated aqueous extract was taken and evaporated to dryness. The dried 
mass was dissolved in water. The dissolved mass is transferred into 50ml of absolute alcohol 
drop wise. The precipitate formed was allowed to settle for one hour and was filtered through 
tarred sintered crucible. The precipitate was weighed and amount was calculated. 
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5.5.2 Estimation of Carbohydrates 
Weigh 100mg of sample in a boiling tube. Hydrolyze by keeping it in a boiling water 
bath for 3 h with 5ml of 2.5N HCl and cool to room temperature. Make the volume to 100ml 
and centrifuge. Collect the supernatant and take 0.5ml and 1ml for analysis. Prepare the 
standards by taking 0.2, 0.4, 0.6, 0.8 and 1.0ml of the working standard. Make up the volume 
to 1ml in all the tubes including the sample tubes by adding distilled water. Then add 4ml of 
anthrone reagent. Heat for eight minutes in a boiling water bath. Cool rapidly and read the 
green to dark green colour at 630nm.  
Calculation 
Sample absorbance x Standard weight x Sample dilution x100 
Standard absorbance x Standard dilution x Sample weight 
5.6 HPTLC Analysis 
 
5.6.1Chromatographic conditions 
 
The experiment was performed on a precoated silica gel 60 F254 (0.2 mm thickness) 
HPTLC plates of E.Merck ,Germany (10x10cm). Samples were applied to the plates as 7mm 
bands, 15mm apart from the edges of the plate, with a Camag Linomat5 sample applicator. 
The plates were developed to a distance of 80mm, in a Camag twin trough glass chamber, 
using a mobile phase chloroform: Methanol (7:1). The saturation time was kept for 30min. 
After development, plates were dried in a hot-air oven, viewed in a Camag UV chamber. The 
chromatograms were scanned using Camag TLC Scanner3. The Rf values and fingerprint data 
were recorded by WINCATS software version 1.3.4. 
 
5.6.2Sample Preparation 
 Refluxed 5g of powdered drug successively with Petroleum ether, chloroform 
and methanol. Filtered and concentrated the methanol extract to dryness. Dissolve 10mg of 
residue in 1ml of methanol.  
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Standard Preparation 
         1.3mg of andrographolide was dissolved in 1ml of methanol. 
5.7  GC-MS Analysis 
 GC-MS analysis was carried out on a GC clarus 500 Perkin Elmer system interfaced 
to a Mass Spectrometer (GC-MS) instrument employing the following conditions: column 
Elite-5m fused silica capillary column (30 x 0.25  mm ID x 0.25μm film thickness, composed 
of crossbond 5% phenyl 95% Dimethyl polysiloxane), Helium (99.999%) was used as carrier 
gas at a constant flow of 1 ml /min and an injection volume of 1.0 μl was employed (split 
ratio of 10:1) injector temperature 290 ºC; ion-source temperature 160ºC. The oven 
temperature was programmed from 50ºC, with an increase of 8 ºC/min to 220ºC hold for 
5min, then 8ºC /min to 280ºC hold for 10 min. Mass spectra were taken at 70eV at a scan 
interval of 0.2 seconds and fragments were scanned from 40 to 600 Da.  
Instrument Details: 
Make  : PerkinElmer Clarus 500 
Software : Turbomass ver5.2.0 
Column Type : Capillary Column Elite-5 (Crossbond 5%Phenyl 95% dimethylpolysiloxane) 
Column length: 30m 
Column id : 250µm  
GC Conditions: 
Oven Rate Temp Hold 
Initial --- 60 0.00 
1 6.0 150 2.00 
2 4.0 280 5.00 
Injector temp.  : 280ºC  
Carrier gas       : Helium @ flow rate 1ml/min 
Split ratio         : 1:10 
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MS Conditions: 
Mass Range  : 40-600amu 
Type of Ionization : Electron Ionization (EI) 
Electron energy : 70ev 
Transfer line and source temperature: 200ºC, 160ºC 
Sample injected : 1.0µL 
Identification of components 
 Interpretation on mass spectrum GC-MS was done using the database of National 
Institute of Standard and Technology (NIST) having more than 62,000 patterns. The spectrum 
of the separated components was compared with the spectrum of NIST library database. The 
identity of the spectra above 95% was needed for the identification of components. 
5.8 FTIR Analysis 
PerkinElmer spectrometer FT-IR Spectrum one in the range of 4000–400cm−1at a   
resolution of 4cm
−1
was used in this analysis that helps to determine the chemical functional 
groups present in the sample which is based on the absorbance of various characteristic 
frequencies by the different functional groups present in the given sample.  
A solid sample about 10 µg was ground well into KBr matrix and analyzed for 
determining various functional groups. The sample was mixed with KBr procured from Merk 
chemicals. Thin sample pellet was prepared by pressing with the Hydraulic Pellet Press and 
subjected to FT-IR analysis.  
5.9 Heavy Metal Analysis (AAS)     
             Atomic Absorption Spectroscopy (AAS) is used for detecting presence of heavy 
metals. Atomic absorption is the process that occurs when a ground state atom absorbs energy 
in the form of light to a specific wavelength and was elevated to an excited state. The amount 
of light energy absorbed at this wavelength increased as the number of atoms of the selected 
element in the light path increases. The relationship between the amount of light absorbed 
and the concentration of analytes present in known standards could be used to determine 
unknown sample concentration by measuring the amount of light, they absorbed. 
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The absorption of light was proportional to the concentration of free atoms in the 
flame. It was given by Lambart-beer law. 
Absorbance = log 10  I0/It =  k.c.l 
Where, 
Io = intensity of incident radiation emitted by the light source.   
It
 
= intensity of transmitted radiation.     
c = concentration of sample (free atoms).      
k = constant        l = path length 
5.9.1 Sample Collection 
 The samples were cleaned and dried under shade. Then, the samples were dried in an 
oven at 40
◦
-50
◦ 
C till a constant weight was obtained. The dried samples were then, ground 
and powdered with agate pestle and mortar. Samples were labeled and stored in pre-cleaned 
polyethylene bottles for further analysis. 
 
5.9.2Reagents and Apparatus 
 All the reagents such as HNO3 and H2O2 used in the study were purchased from 
MERCK (Analytical Grade).  De-ionized water was used for all analytical work and all the 
glassware’s, polyethylene bottles, pipette tips and others were washed with 1 % HCl, rinsed 
with de-ionized water before preparing standards, reagents and samples.  
 
5.9.3Sample Preparation (Ash Method)  
 The collected medicinal plant parts were cleaned and dried under shade. The dried 
part was then, ground to fine powder, which was used for drying to ashing. Necessary 
precautions were taken at every step to avoid metallic contamination in any form. Pre-cleaned 
silica crucibles were kept in muffle furnace maintained at 600
o 
C.  Until the weight of the 
crucible reached a constant level, the crucible was kept in the furnace. Powdered plant 
material (5 gm) were taken in the silica crucible and maintained in a muffle furnace at 600
o 
C 
for 6 hrs. The crucible were then, taken out and cooled at room temperature by keeping it in a 
desiccator and then, the ash values were measured. Then, the ash was dissolved in 100 ml of 
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5 % HCL. The dissolved ash solutions were filtered through Whatman filter   paper No.40 
and are stored in tightly capped plastic bottles. The prepared solutions were directly subjected 
to flame photometry and AAS for the estimation of various elemental concentrations.  
 
5.9.4Digestion of Samples  
  A Multiwave 3000 micro oven system (from Anton paar, USA) with 16 positions for 
Teflon vessels with capping was being used here. The digestion vessels were provided with a 
controlled pressure, temperature and release valve. Before use, all Teflon vessels were soaked 
with 10 % HNO3. The system was initially programmed by giving gradual rise of 20 %, 40 
%, and 50 % power for 5, 15 and 20 minutes, respectively for the due warming up. The 
powder samples were being used without any further treatment for sample preparation. 0.2 
gm of sample was weighed into the Teflon vessels followed by digestion mixture of HNO3 
and H2O2 in the ratio of 3:1. According to the nature of samples, the ratio was being applied. 
The resulting solution after microwave digestion was filtered through Whatman 40 filter 
paper (if necessary) and diluted to 50 ml with de-ionized water. A sample blank containing 
only acid mixture was prepared at the same time.  The method of standard addition was 
generally adapted to calibrate the instrument before going for the observation of the samples.  
 
5.9.5Determination of Metals 
All the atomic measurements were carried out with PerkinElmer model 
400/HGA900/AS800 coupled with Mercury Hydride System-15 (MHS-15) and Flame 
Photometer. The Electrodeless Discharge Lamp (EDL) for Cd, Pb, Hg and As analyses were 
used as a light source to provide specific wavelength of the elements to be determined High 
purity (99.999 %) Acetylene and Nitrous oxide were used to provide constant thermal energy 
for atomization process and Argon gas used for carrier gas purging purposes for Graphite 
furnace.  
 
Calibration of Instruments 
More than three working standard solution of elements to be determined were 
prepared, covering the concentration range as recommended by the manufacturer of the 
instrument for the elements to be determined. Before the analysis of samples, the instruments 
were calibrated with prepared working standard solution. The calibration curve was obtained 
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for concentration vs. absorbance and data obtained was statistically analyzed. Calibration of 
the instrument was repeated periodically during operations and blanks were carried with each 
set of 10 samples or aspirated any one of the prepared working standard for every 10 samples 
to check the instrument drift and to validate analytical procedures and performance. Regent 
blank reading would be taken and necessary correction would be made during the calculation 
of concentration of various elements. Standard Certified Reference of National Institute of 
Standard and Technology (NIST) was used for day-to-day, and for the evaluation of methods 
of analysis or test and also for long-term quality assurance of measurements. A reagent blank 
reading was taken and necessary corrections were made during the calculation of 
concentration of various elements (Eng-Shi et al., 2000 and Sahito et al., 2001). 
 
5.10 Microbial Analysis  
 Materials containing microorganism were cultured. Each viable organism developed 
into a colony. Hence, the number of colonies appearing on a plate represented the number of 
living organisms present in the given sample. 
Procedure 
 Plant material samples were obtained and thoroughly mixed to make composite 
sample for microbial analysis. 10 gm of appropriate plant material was weighed and 100 ml 
of sterile distilled water in a sterilized conical flask were placed for serial dilution. The flasks 
were kept in a mechanical shaker for five minutes to obtain uniform suspension of 
microorganisms. The dilution level was 1-10 or 10
-1
.  From this, 1 ml of dilution from 10
-1
 
sample was taken out and if transferred into 9 ml, this was 10
-2
 dilution. The procedure was 
repeated up to 10
-6
 dilution. Transfer 1ml of serial dilution from10
-1
 to 10
-6
 into sterilized 
petri-plates for enumerating bacteria, fungi and severe pathogens such as Salmonella, 
Shigella and E.coli. Two replications are maintained to each dilution, in each group of 
microorganisms. The medium such as Nutrient Agar (NA), Potato Dextrose Agar (PDA), 
Salmonella Shigella Agar (SS) and Eosin Methylene Blue Agar (EMB) were added to the 
sterilized petri-plate with one mL sample, and rotating the plate clockwise and anti clockwise 
to get an uniform distribution of microbial cells. 
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The medium was allowed to set and the plates were incubated in inverted position at 
37
0
C for about 1-2 days for bacteria and 3-5 days for fungi. The colonies were counted on the 
plates with the aid of colony counter. The numbers of colonies were observed from both the 
plates, which were kept for replication. The total numbers of population were enumerated 
individually for fungi and bacteria by taking the average of the two dilutions employed and 
expressed in 1 gm of plant material. 
 
5.11 X-ray Fluorescence spectrometer (XRF) 
Method 
XRF is a technique that measures the concentration of elements present in a given 
sample through detection of secondary electrons.  
 
Equipment 
Instrument: XRF Bruker S8 Tiger 
X-ray fluorescence spectrometry: Two grams of boric acid were filled in aluminium 
cups and then 1 gram of each sample was evenly spread over it. The aluminium cups were 
pelletized using a hydraulic press at 25 tons to obtain pellets. Samples were analyzed using 
XRF spectrometer (Bruker S8 Tiger) equipped with a 4KW, Rh anode X-ray tube. 
 
5.12 In vitro studies 
In vitro cytotoxicity studies 
Evaluation of cytotoxicity of aqueous extract of Nilavembu Kudineer 
Methodology 
Extract preparation  
The Siddha drug Nilavembu Kudineer was purchased from authorized dealer at 
Trichy. This drug was manufactured by The Indian Medical Practioners Co-operative 
Pharmacy and Stores Ltd, Thiruvanmiyur, Chennai. This drug was composed of Seemai 
Nilavembu (Andrographis paniculata Burm. f), vettiver (Vetiveria zizanioides L.), 
vilamichamver (Plectranthus vettiveroides Jacob), santhanam (Santalum album L.), peipudal 
(Trichosanthes cucumerina L.), koraikizhangu (Cyperus rotundus L.), chukka (Zingiber 
officinale Roscoe), milagu (Piper nigrum L.) and parpatakam (Mollugo cerviana L. Ser). The 
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aqueous extract was prepared by taking 25 g of Nilavembu Kudineer raw material in 500 ml 
of distilled water and boiled at 90°C until the final volume reaches to 100 ml. Then the 
content was filtered and the filtrate was frozen and then lyophilized. The extract yield was 
found to be 1.32 g/100 g drug. The extract was re-suspended in water at 10 mg/ml ratio and 
used for the cytotoxicity experiment. 
 
Evaluation of cytotoxicity  
The 3T3-L1 pre-adipocytes were obtained from the National Center for Cell Science 
(NCCS), Pune and cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 
10% fetal bovine serum (FBS) and penicillin (100 U/mL)-streptomycin (100 μg/mL) in a 
humidified atmosphere of 95% air and 5% CO2 at 37°C. After arriving 60% of confluency, 
the cells were trypsinized and dispersed in a 96 well plate with a cell count of 9000 cells per 
well and incubated for 24 h. Then the aqueous extract was added at different concentrations 
(10, 5, 2.5, 1.25 and 0.625 mg/ml) and then again incubated for 24 h. The cell group grown in 
medium without plant extract was considered as control. At the end, the medium was 
discarded, cells are washed with PBS and then MTT reagent (20 microliter) was added in 
each well and incubated for 6 h at 37
°
C in a water bath. Then 150 µl of acidic isopropanol 
was added and shaken for 30 min on a plate shaker under dark. The absorbance was measured 
at 540 nm in a micro-plate reader and the cell viability was calculated and expressed in 
percentage basis. 
 
5.13 Pre- Clinical Studies 
5.13.1 Acute Oral Toxicity Study 
Acute Oral Toxicity Study of Nilavembu Kudineer (NVK) in rats was performed as 
per Organization for Economic Cooperation and Development (OECD) Test Guidelines - 425 
for the conduct of Acute Oral Toxicity (Up and Down Procedure) with slight modifications 
was followed (OECD, 2008).  All procedures involving laboratory animal use were in 
accordance with the Institute Animal Ethics Committee (IAEC) regulations approved by the 
Committee for the Purpose of Control and Supervision of Experiments on Animals 
(CPCSEA) and the approval number is 357/SASTRA/IAEC/RPP.  
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5.13.2Selection of animals 
Healthy female Wistar Rats (Rattus norvegicus) between 8 and 12 weeks old and 
individual body weights falling within ± 20 % of the mean initial body weight were selected 
for the present study. The female rats used for the present study were nulliparous and non-
pregnant.  
 
5.13.3Identification of Animals  
 Tags  marked  with  animal  number,  group  number  and  dose  level  were  attached  
to  the respective cages. Each animal was identified by unique identification number by ear 
tagging. 
Table: 5 Identification of Animals 
Animal ID Sex 
6022 Female 
6023 Female 
6024 Female 
6025 Female 
6026 Female 
Acclimatization 
 Animals were acclimatized to the study environment for a week prior to drug 
treatment. During the acclimatization period, all the animals were observed for clinical signs 
once a day. At the time of receipt of animals and completion of the acclimatization period, the 
body weights were measured using the automatic animal balance (Sartorius, Germany). 
 
Animal Husbandry 
Animal House Condition 
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        Temperature of the test room was maintained between 22±3°C and relative humidity 
between 50 to 70% during the experimental period. The experimental room was provided 
with a 12h light and 12h dark lighting condition using an automatic timer. 
 
Housing 
 Standard polypropylene rat cages with stainless steel top grill was used to house the 
animals. The cages were autoclaved.  Sieved and sterilized paddy husk was used as the 
bedding material. Animals were housed individually. 
 
Sanitation 
 Bedding material , cages, grills and water bottles were changed weekly twice. 
 
Animal Welfare and Regulatory Compliance 
 The experiment was conducted at the Central Animal Facility registered 
(No.817/04/ac/CPCSEA dated11.03.99) for Breeding and Experiments of Animals by the 
Committee for the Purpose of Control and Supervision of Experiments on Animals, Ministry 
of Forest and Environment, Govt. of India. 
 The study was conducted after the approval by the Institutional Animal Ethical 
Committee, SASTRA University (IAEC Approval Number: 357/SASTRA/IAEC/RPP). 
 
Diet and Water 
 Standard  rodent pellet feed supplied by M/s. ATNT Laboratories, Mumbai, India and 
Reverse Osmosis (RO) water were provided to the animals ad libitum. 
 
Preparation of Test Substance 
 The test substance, Nilavembu Kudineer was dissolved in distilled water. The test 
substance was prepared freshly before dosing and the dose was calculated as per the body 
weight of individual animals.   
 
5.13.4Experimental Plan 
Healthy Female Albino Wistar rats were selected for the studies and administered 
with a single oral dose of aqueous extract of Nilavembu Kudineer at the dose of 2000 mg/kg, 
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b.wt by oral route dissolved in 1 mL of distilled water used as the vehicle. Each animal was 
observed for every 15 min in the first 4 h after dosing, then every 30 min for the successive 6 
h and then daily for the successive 48 h for the short-term outcome and the remaining 14 days 
for the long-term possible lethal outcome which in this case was death. The animals were 
observed for signs of convulsions, tremors, circling, depression, excitement and mortality. 
The surviving animals were sacrificed under CO2 inhalation euthanasia, autopsied and 
examined macroscopically for any pathological changes.  
 
 Mortality 
All animals were observed twice everyday for mortality for 14 days. 
 
Body Weight 
Body weight of each animal was recorded just prior to the test substance treatment on 
Day 0, Day 7 and Day 14 using electronic Animal weighing balance (Sartorius AG, 
Germany). 
 
Feed Intake 
Feed intake for individual animals was recorded daily for the entire study period. 
 
Table:6 Dosing schedule for individual animals 
Animal ID Dose (mg/kg) Observations 
6022 2000 Survived 
6023 2000 Survived 
6024 2000 Survived 
6025 2000 Survived 
6026 2000 Survived 
 
 
OBSERVATIONS 
Observation Period: 14 days 
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5.13.5Clinical signs observations  
During the observation period, the drug treated animals were observed for its clinical signs of 
toxicity just before the administration, at 30 minutes, 1, 2, 3, 4 and 8 hours after the 
administration and at least once a day from day 1 till 14. Clinical signs including mortality, 
morbidity, general appearance (skin and fur, eye and mucous membrane, nervous system etc.) 
and behavior were recorded. The clinical observations such as faeces, colour and consistency, 
clear ocular discharge, hyper activity, skin and fur examination, tremor and convulsion, pilo 
erection, change in gait, repetitive circling and excessive grooming were observed in all test 
drug treated experimental animals. 
 
Gross Pathology 
 All animals subjected to necropsy were showed no gross pathological changes. 
 
5.13.6 ANTI-DIABETIC SCREENING STUDIES 
Anti-diabetic screening of Nilavembu Kudineer against Streptozotocin (STZ)-Induced 
Diabetics in Rats (Syed A Hassan et al., 2012) 
 
Table: 7 Experimental Design 
Groups Descriptions 
No. of 
Animals 
Treatments 
I Normal control 6 Distilled water 
II Diseased control 6 Streptozotocin (STZ, 65 mg/kg, i.p) 
III Standard 6 
STZ (65 mg/kg, i.p)+ Metformin (100 
mg/kg, p.o) 
IV NK - Low dose 6 
STZ (65 mg/kg, i.p)+ Nilavembu 
Kudineer (100 mg/kg, p.o) 
V 
NK - Medium 
dose 
6 
STZ (65 mg/kg, i.p)+ Nilavembu 
Kudineer (200 mg/kg, p.o) 
VI NK - High dose 6 
STZ (65 mg/kg, i.p)+ Nilavembu 
Kudineer (400 mg/kg, p.o) 
 
NVK- Nilavembu Kudineer, p.o.-per oral, STZ-Streptozotocin, i,p-intraperitoneal 
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5.13.7Experimental procedure 
The diabetes mellitus was induced by a single intraperitoneal injection of 
Streptozotocin (STZ, 65 mg/kg) dissolved in 0.1M citrate buffer (pH 4.5) in fasted male 
Wistar rats. The control group rats were treated with distilled water. The Diabetes was 
confirmed at 48 h after STZ injection by measuring the glucose concentrations of peripheral 
blood, obtained from the tail vein using glucometer (ASPEN AP +PLUS). Rats with blood 
glucose levels of 250 mg/dl or higher were considered to be diabetic and were grouped into 
five groups each containing eight rats (Akbarzadeh et al., 2007). The diabetic induced rats 
were treated with standard/vehicle/test drug orally as per the study protocol (Table7) for 4 
weeks. The change in body weights were measured weekly. During the last week of drug 
treatment, experimental rats were housed in metabolic cages and the changes in feed intake, 
water intake and urine output were measured and calculated.  At the end of the experiment, 
all the rats were fasted overnight and blood samples were collected by retro orbital puncture 
under anesthesia. The blood samples were collected in clot activator tubes and allowed to clot  
for 10 minutes, centrifuged at 2500 rpm for 15 minutes to obtain serum. The serum layer was 
collected in properly labeled, clean and micro-centrifuge tubes and analyzed immediately for 
biochemical parameters such as glucose, total protein, Albumin, Creatinine, Urea, total 
cholesterol and triglycerides levels.  
 
5.14 Clinical Studies 
  
 Acute oral toxicity studies for Nilavembu Kudineer was performed as per OECD – 
425 guidelines from the toxicity results it was observed that there was no significant changes 
in weekly bodyweight and also daily behavior observation. It is concluded from the study that 
the drug is safe upto 2000 mg/kg when administered orally. After ascertaining the anti 
diabetic efficacy of Nilavembu Kudineer in pre clinical studies conducted using STZ induced 
diabetic rat models and ascertaining nontoxic nature of the test drug Nilavembu Kudineer, a 
pilot scale clinical study was under taken.  
5.14.1 Ethical clearance  
 Institutional Ethical Committee (IEC) of National Institute of Siddha, Tambaram 
Santorium, Chennai, approved the protocol before the initiation of the trial of Nilavembu 
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Kudineer in diabetic subjects.  This clinical trial is registered in Clinical Trial Registry of 
India (CTRI) New Delhi. 
 Clinical study was conducted as per the guidelines for Good Clinical Practice 
accepted by AYUSH adapted from the International Conference on Harmonization (ICH).  
The clinical study was carried out in two phases as pilot study and as main study. 
Study design: Open clinical trial. 
Sample size: Sample size arrived was 60 
Study Centre: Ayothidoss Pandithar Hospital, National Institute of Siddha, Tambaram, 
Chennai- 47. 
Treatment period:  90 days and follow-up period for 1 month.  
Study population: Diabetic Patients in the age group of 30 to 60 years, both male and female  
5.14.2Inclusion criteria 
1. Both the sexes. 
2. Age group of 30 to 60 years with history of NIDDM for less than 5 years were 
included. 
3. Newly diagnosed of NIDDM patients from Out Patient Department, Ayothidoss 
Pandithar Hospital, were included in this study 
4. Patients with or without symptoms like polyuria, polydipsia, polyphagia and weight   
     loss were included in this study 
 
5.  Blood glucose levels: 
Fasting glucose level        :   > 126 mg/dl     to   < 250 mg/ dl 
Post prandial glucose level :  > 200 mg/dl      to   < 400 mg/ dl 
HbA1c                               :    6.5 mmol/l        to    8 mmol/l 
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5.14.2Exclusion Criteria 
1. Patients below 30 years and above 60 yrs. 
2 Insulin dependent Diabetes Mellitus 
3. Gestational Diabetes 
4.  Diabetes patients with complications 
5. Known diabetic patients for more than 5yrs were excluded 
6. Insulin dependent diabetes mellitus. Gestational diabetes / lactating   
            and pregnant women  
 
 
 
Withdrawal criteria 
Subjects with severe occurrence of adverse events or signs of severity were excluded 
from the clinical trial. These patients were withdrawn from the clinical trial studies.  
 
  5.14.3Laboratory Diagnostic Parameters 
Patients were screened for following Laboratory Diagnostic Parameters. 
Hematology: Hb, TC, DC, TRBC, PCV, MCV, PLT, ESR. 
Liver function tests: Serum bilirubin, SGOT, SGPT, Serum Alkaline Phosphatese. 
Renal function tests: Blood urea, Creatinine, total Protein, Albumin, globulin, uric 
acid. 
Urine examination: Fasting Urine Sugar, Postprandial urine sugar, Albumin, Pus 
cells, epithelial cells. Deposits, Bile salt, Bile pigments.  
 Blood:   HbA1c.  
 Lipid profile: cholesterol, HDL, LDL, VLDL, TGL. 
 Urine examination: ketones, pH of urine, Specific gravity. 
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5.14.3Siddha Diagnostic Parameters 
They were evaluated for following Siddha diagnostic parameters 
 Thinai, Theganilai, Noyinmukkutranilai,  saptha thadhukkal, migugunam, 
kuraigunam, Uyirthadhukal migugunam, kuraigunam,  
 Envagaithervugal Na, niram, mozhi, vizhi, sparisam, malam, moothiram-  Neerkuri, 
Neikuri, Naadi. 
 
Table: 8 Treatment Regimen 
 
 
Patients of age group between 30yrs and 60 yrs of both sexes who visited Out-Patient 
Department of National Institute of Siddha, Chennai-47 with the symptoms of polyuria, 
polydipsia, and polyphagia were included in this study.  Patients having history of Diabetes 
Mellitus prevailing less than 5 years were recruited in this study after informing and getting 
written consent from them that they were willing to take part in the anti diabetic screening of 
Nilavembu Kudineer and for evaluating HbA1c, fasting and post prandial blood sugar levels. 
 The patients who were under the treatment for diabetes were asked to withdraw 
previous medicines for one day before initialing the study drug clinical trial. The history, 
symptoms, and signs were recorded in the case sheet. Nilavembu Kudineer 60 ml was given 
to selected human subjects for 7days. Before starting the treatment, patients were instructed 
about dosage, mode of administration, frequency of administration of Nilavembu Kudineer. 
The patients were advised to follow the diet restrictions, exercise and yoga as stated in the 
S. No. Drug Administration Protocol  
1 Study drug Nilavembu Kudineer 
2 Route of Administration      Oral administration 
3 Dosage of the Medicine               30 -60 ml once  
4 Duration of the Treatment           90 days 
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literature. The patients were asked to come for review once in 7 days and to collect the study 
medicine. In addition to Fasting and postprandial urine sugar, ketone bodies analysis were 
done in urine test.  Signs and symptoms of hypoglycemic conditions and hyperglycemic 
conditions were explained to the patients and their relatives to identify the severity of the 
disease.  Patients were informed about the adverse effects i.e. rashes, vomiting diarrhoea, etc. 
and asked to inform immediately in case of to the Principle Investigator.  
 No one from study population reported adverse effects.  Patients were examined and 
signs and symptoms were recorded in the case sheet. The blood sugar test for Fasting and 
Post Prandial were carried out to assess the prognosis of the disease. Complete Blood Count, 
Renal profile, Liver function test, Lipid profile, Total protein, albumin, Globulin, and uric 
acid were done on 0 day and repeated on 90
th
 day to assess the prognosis of the disease and 
efficacy of the study drug. 
5.14.4Informed consent 
Participants were informed well about the research study, risk and benefits of 
participation. After getting their voluntary consent they were enrolled for the study.
 
Pilot study 
Initially, a Pilot study was conducted to validate the study protocol.  
Main study   
After the pilot study, main study was carried out. 
Medicine intake chart was provided to mark an entry of intake of the medicine for 90 
days. All the patients had the Nilavembu Kudineer 60 ml once daily regularly without any 
break. 
 
5.14.5 Assessment of the Siddha parameters 
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Theganilai (Body Constitution) and Noinilai (Disease condition) were assessed 
initially. According to the Siddha concept, Thinai (Land Tract)of the patients were recorded. 
Food habits responsible for the occurrence of diabetes, according to the Siddha concept were 
recorded.  Changes in the Ennvagaithervu i.e., Na (Tongue), Niram (Colour of the Body), 
Mozhi (Speech), Vizhi (Vision), Sparisam (Palpation), Malam (Stools), Moothiram (Urine)- 
Neerkuri, Neikuri and Naadi were examined and recorded in the case sheet for all the 
patients. No one from the study participants was reported of adverse effects during the 
treatment period and follow up period, 
        On completion of the study period, the patients were followed up for a year.  During that 
period, patients were asked to come for review every 15 days and the study drug was 
administered throughout the follow up period.  HbA1c test was done before and after 
treatment. 
5.14.6Follow-up visits were needed to 
1. Carryout procedures specified in the study protocol, including treatment administration 
2. Evaluate the patient’s response to treatment 
3. Assess patient adherence to the assigned treatment 
4. Collect data needed for evaluation of the treatment such as to assess the. 
Rate of occurrence of the outcome(s) of interest 
Patient health care 
Patient convenience considerations 
 
    Table:9 Parameters observed to assess the efficacy of the selected drug 
 
S. No 
 
Parameters 
 
0 Day 
 
30
th
 Day 
 
45
h
 Day 
 
60
 th
  Day 
 
90
 th
  Day 
1. Polyphagia A A A A A 
2. Polydypsia A A A A A 
3. Polyuria A A A A A 
4. Loss of 
weight 
A A A A A 
5. Pain/cramps A A A A A 
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6. Blood sugar  
FBS/PPBS 
A A A A A 
7. Haemogram A NA NA NA A 
8. Cholesterol A NA NA NA A 
9. Triglycerids A NA NA NA A 
10. Hb A1c A NA NA NA A 
11. LFT A NA NA NA A 
12. KFT A NA NA NA A 
 
 A – Applicable 
 NA – not applicable 
 FBS – Fasting blood sugar 
 LFT – Liver function test 
 PPBS – Post prandial blood sugar 
 KFT – Kidney function test 
 
5.14.7Outcome Measures 
Primary outcome 
 Blood glucose and changes of clinical symptoms. 
 
Secondary outcome 
 Relief from symptoms such as, Poly urea, poly phagia, polydypsia ,itching and 
numbness, changes in other investigatory parameters were taken into account.  
 
5.14.8Periodical report on the patients 
 All measurements and parameters were observed regularly. Priority was given for the 
tests mentioned in the case record form and the reports recorded periodically for ascertaining 
the efficacy and for observing the statistical significance. 
  
 On receiving the results the patients were called for individual counseling and further 
proceedings. After this process of finishing the initial measurement parameters and screening 
of general information, the study was initiated with the 0 day as the starting point with a diet 
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list – Pathiyam as per Siddha system which was given to each subject for adhering to it 
strictly throughout the study period of 180 days. 
 
 
5.14.9Data processing 
During this study piling up of patients records for a long time is avoided. Organized 
check was followed on trial progress in the early stages. Data processing for statistical 
analysis was filled right from very beginning.  
In this study on the anti-diabetic efficacy of Nilavembu Kudineer, a collection of 
observations were recorded of the subjects for 90days, (the study period) and consolidated as 
a data.  They were condensed and presented in the form of a table to improve communication. 
The table helped the investigator to grasp the overall nature of the data. 
 
 5.14.10 Statistical analysis 
 All the demographic and clinical and investigative data which were entered into the 
case recording form were exported into an excel sheet. The variables were coded and entered 
in the data sheet. The cumulative data sheet was electronically maintained to facilitate the 
data analysis by using the SPSS software. 
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Chapter - VI 
Results 
6.1 Botanical studies 
Powder microscopy of Nilavembu kudineer revealed the presence of prismatic, 
acicular and druses type of calcium oxalate crystals.  Unicellular, uniseriate and stellate non 
glandular trichomes are seen with smooth and warty surface. Lumen is wide and narrow.  
Uniseriate glandular trichomes are present with and without heads and the cells are filled with 
cellular contents. Some of the trichomes are seen with degenerated cells. Simple and 
compound starch grains present with striated margin. Peaked, hilum acentric and fissured. 
Compound starch grains contains di, tri, tetra or many grains. Macro, brachy and 
trichosclereids are seen with pitted, striated thick lignified cell wall. Lumen is wide and 
narrow, branched and simple.  Libriform and tracheid fibres are seen with simple and 
bordered pits and the ends are tapering and blunt, some of the fibres are bifurcated. Testa is 
made up of sclerenchymatous thick walled pitted cells with branched narrow and simple wide 
lumen and minute pores are seen in corners where the two cells are joined.  The xylem 
vessels are long and narrow or short and wide tailed with simple and bordered pitted, 
scalariform, reticulate and spiral thickenings.  Epidermal cells are wavy, straight and beaded 
with druses of calcium oxalate crystals. Some of the cortical cells are thick with lignified 
walls, containing prismatic calcium oxalate crystals.   
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    Table:10 Cells and cell inclusions of Nilavembu Kudineer 
 
 
 
 
 
 
 
 
 
 
 
 
S. No Cells/ cell inclusions Size in µm 
1 Xylem vessels 140 - 248 
2 Tracheids 142 - 231 
3 Fibres 257 - 312 
4 Tracheary 260 – 313 
5 Sclereids 172 – 249 
6 Stone cells 35 - 71 
7 Epidermal cells 56 - 60 
8 Parenchyma cells 88 - 145 
9 Unicellular trichomes 140 - 241 
10 Uniseriate trichomes 77 - 150 
11 Glandular trichomes 167 - 189 
12 12 Stellate trichome 96 - 135 
13 Prismatic calcium crystals 18- 27 
14 Acicular crystals 80 - 94 
15 Starch grains 18 – 31 
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Powder microscopy of Nilavembu Kudineer revealed the presence of all the 
ingredients mentioned in the Siddha text. The unique microscopic features of the ingredients 
of Nilavembu Kudineer observed were compared with the microscopic characters of 
individual ingredients which are mentioned in the Siddha Pharmacopoeia and other literature. 
 
This literature comparison suggested presence of all the ingredients in Nilavembu 
Kudineer. Unique botanical characters observed in the present study for ingredients of 
Nilavembu Kudineer is discussed in sequel.  
 
Tailed xylem vessels with pitted thickening, rectangular parenchyma cells, prismatic 
calcium oxalate crystals and oil globules (Santalum album); Tracheids fibres with branching 
and split ends, libriform, thin walled, tapering end with wide lumen, round to oval starch 
grains, prismatic calcium oxalate crystals, vessels with simple pitted and scalariform 
thickening, parenchyma cells with reticulation (vilamichaiver - Plectranthes vettiveroides).  
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Epidermal cells are wavy, sclerenchyma cells with narrow lumen, tracheids are thick 
walled, brown colour seeds, tricolpate pollen grains and group of fibres (papatakam- Molluco 
cerviana). Brown content, slightly elongatedand beaker shaped stone cells, stone cells, 
minute compound and simple starch grains (milagu – Piper nigrum). Round to oval shaped 
starch grains and groups of fibres (vettiver- Vettiveria zizanioides). Septate and crisscross 
fibres, vessels with reticulate and spiral thickening, brown content and striated starch grains 
(chukku-Zingiber officinale). Vessels with reticulate and simple pitted thickening, fibre like 
sclereid cells, narrow xylem vessels with scalariform thickening (koraikizhanku – Cyperus 
rotundus). Acicular calcium oxalate crystals, xylem vessels with spiral and pitted thickening, 
unicellular and short and long uniseriate trichomes with bi and tri cellular, short and long 
uniseriate multicellular headed glandular trichome, spherical shaped pollen grains 
(Nilavembu-Andrographis paniculata). Polygonal cork cells, striated sclereids are 
isodiametric or in various shapes with round branched lumen, grouped fibres, xylem vessels 
with reticulate and bordered pitted thickenings (peipudal – Trichosanthes cucumerina). 
 
Histochemical analysis using various chemical reagents revealed the presence of 
lignin, starch, oils, fats and resins. Presents of calcium oxalate crystal were also confirmed 
through this technique.  
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6.2Chemical Standardization Studies 
The data of the results obtained on chemical standardization studies such as test for 
identity, purity and strength determined were also given Table11. Besides HPTLC and GC-
MS analysis were also performed and the results were also given. XRF analysis was carried 
out to detect the presence of various metals and minerals. Microbial load and heavy metal 
analysis were also performed to check the contamination. 
 Table:11 Tests for identity, purity and strength 
 
 
6.4Preliminary phytochemical screening 
Preliminary phytochemical screening revealed the presence of various bioactive 
compounds like alkaloids, sterols, terpenoids, saponins, carbohydrates and mucilage in 
Nilavembu Kudineer. The tests for flavonoids, tannins and phenols gave negative results, 
which indicated their absence in Nilavembu Kudineer.  
 S. 
No 
Parameters Results Range 
1 Appearance 
Brown coloured fine 
powder 
- 
2 pH (1% w/v solution) 6.82 4-14 
3 Total Ash 30.13%w/w 1-25% 
4 Acid Insoluble Ash 1.791%w/w 0.1-10% 
5 
Loss on Drying at 
105°C 
5.739%w/w 1-20% 
6 
Water Soluble 
Extractive(WSE) 
81.07%w/w 4-85% 
7 
Alcohol Soluble 
Extractive(ASE) 
3.589%w/w 4-85% 
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Table:12 Estimation of Alkaloids, Carbohydrates and Mucilage 
 
 
 
 
 
 
6.5 HPTLC analysis 
 The HPTLC analysis of Nilavembu Kudineer revealed the presence of 11 spots with 
Rf at 0.31, 0.55, 0.58, 0.65, 0.70, 0.77, 0.82, 0.88, 0.92, 0.95 and 0.97 under 254 and 366 nm. 
The Rf value 0.70 indicates the presence of Andrographolide, the marker compound.  
HPTLC Finger printing studies 
        HPTLC FINGERPRINTING PROFILE OF   Nilavembu Kudineer Churnam 
                       PHOTO DOCUMENTATION UNDER UV 
 AT 254nm                                                                               AT 366nm 
 
 
 
 
 
 
 
 
 
 
S No Constituents estimated  Results 
1 Alkaloids 0.9322% 
2 Carbohydrates 35.28% 
3 Mucilage 0.1692% 
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TLC DETAILS 
 S1-10µl of standard Andrographolide, T1-10µl of sample Solution, T2-10µl of 
sample Solution 
 
 
 3D DISPLAY AT 254nm 
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PEAK DISPLAY (10µl of Standard)                     PEAK DISPLAY (10µl of Sample) 
 
 
 
 
 
 
                
FIG-I                                                                                           
FIG-II 
 
       
  
 
 
 
 
 
 
 
PEAK DISPLAY (20µl of Sample)                                        
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The HPTLC analysis of Nilavembu Kudineer revealed the presence of 11 spots with 
Rf at 0.31, 0.55, 0.58, 0.65, 0.70, 0.77, 0.82, 0.88, 0.92, 0.95 and 0.97 under 254 and 366 nm. 
The Rf value 0.70 indicates the presence of Andrographolide, the marker compound.   
 
 
6.6 GCMS –Studies: 
Chromatogram 
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Table:13 List of compounds identified in GCMS 
 
S.No. Peak Name Retention 
time 
Peak area %Peak 
area 
1.  Name: 2-Butanol, 3-methyl- 
Formula: C5H12O 
MW: 88 
4.71 277476 0.4246 
2.  Name: 1,3-Propanediamine, N-
methyl- 
Formula: C4H12N2 
MW: 88 
8.38 406999 0.6228 
3.  Name: Homopiperazine 
Formula: C5H12N2 
MW: 100 
10.49 238174 0.3645 
4.  Name: Decanal 
Formula: C10H20O 
MW: 156 
10.60 306506 0.4691 
5.  Name: Piperonal 
Formula: C8H6O3 
MW: 150 
13.84 101365 0.1551 
6.  Name: Phenol, 2,4-bis(1,1-
dimethylethyl)- 
Formula: C14H22O 
MW: 206 
18.14 912183 1.3959 
7.  Name: Bicylo[4.1.0]heptane, 7-
bicyclo[4.1.0]hept-7-ylidene- 
Formula: C14H20 
MW: 188 
19.40 163449 0.2501 
8.  Name: Tridecanoic acid 
Formula: C13H26O2 
MW: 214 
19.60 689803 1.0556 
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9.  Name: 
Tricyclo[2.2.1.0(2,6)]heptane-3-
methanol, 2,3-dimethyl- 
Formula: C10H16O 
MW: 152 
Teresantalol 
21.08 91218 0.1396 
10.  Name: 2-Butanone, 4-(4-hydroxy-
3-methoxyphenyl)- 
Formula: C11H14O3 
MW: 194 
Zingerone 
21.97 238658 0.3652 
11.  Name: Santalol, cis,à- 
Formula: C15H24O 
MW: 220 
22.10 31752 0.0486 
12.  Name: Santalol 
Formula: C15H24O 
MW: 220 
22.62 1168835 1.7887 
13.  Name: 2-Decanone 
Formula: C10H20O 
MW: 156 
22.94 132709 0.2031 
14.  Name: à-Santalol 
Formula: C15H24O 
MW: 220 
23.77 522339 0.7993 
15.  Name: 7-Acetyl-2-hydroxy-2-
methyl-5-
isopropylbicyclo[4.3.0]nonane 
Formula: C15H26O2 
MW: 238 
24.39 512413 0.7842 
16.  Name: 9H-Pyrido[3,4-b]indol-7-ol, 
1-methyl- 
Formula: C12H10N2O 
24.83 562926 0.8615 
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MW: 198 
Name: 4-Phenoxybenzaldehyde 
Formula: C13H10O2 
MW: 198 
17.  Name: Tetradecanoic acid 
Formula: C14H28O2 
MW: 228 
25.06 1492063 2.2833 
18.  Name: 1H-3a,6-Methanoazulene-3-
carboxylic acid, octahydro-7,7-
dimethyl-8-methylene-, [3S-
(3à,3aà,6à,8aà)]- 
Formula: C15H22O2 
MW: 234 
Vetivenic acid 
26.56 8733962 13.3658 
19.  Name: 3,5,7-Nonatrien-2-one, 8-
methyl-7-(1-methylethyl)-, (E,E)- 
Formula: C13H20O 
MW: 192 
28.10 798144 1.2214 
20.  Name: Andrographolide 
Formula: C20H30O5 
MW: 350 
28.60 1384370 2.1185 
21.  Name: Naphthalene, decahydro-
1,1-dimethyl- 
Formula: C12H22 
MW: 166 
29.44 897201 1.3730 
22.  Name: Bicyclo[2.2.1]heptane, 2-
methyl-3-methylene-2-(4-methyl-3-
pentenyl)-, (1S-endo)- 
Formula: C15H24 
MW: 204(Epi-á-Santalene) 
29.71 354926 0.5432 
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23.  Name: n-Hexadecanoic acid 
Formula: C16H32O2 
MW: 256 
30.25 9997901 15.3000 
24.  Name: 3,7,11,15-Tetramethyl-2-
hexadecen-1-ol 
Formula: C20H40O 
MW: 296 
33.41 409889 0.6273 
25.  Name: 2-Methyl-Z,Z-3,13-
octadecadienol 
Formula: C19H36O 
MW: 280 
34.44 8832656 13.5168 
26.  Name: (-)-Nortrachelogenin 
Formula: C20H22O7 
MW: 374 
36.19 755638 1.1564 
27.  Name: Gingerol 
Formula: C17H26O4 
MW: 294 
36.35 1552711 2.3762 
28.  Name: Gingerol 
Formula: C17H26O4 
MW: 294 
37.79 5788098 8.8577 
29.  Name: Acetic acid, 1-[2-(2,2,6-
trimethyl-bicyclo[4.1.0]hept-1-yl)-
ethyl]-vinyl ester 
Formula: C16H26O2MW: 250 
42.57 1924017 2.9444 
30.  Name: Piperine Formula: 
C17H19NO3MW: 285 
48.89 16067177 24.5880 
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The data obtained on GCMS analysis of Nilavembu Kudineer showed fragmentation 
pattern of flavonoids and piperine which is evident in the chromatogram also.  
The GC-MS analysis further showed the presence of vetiveric acid, palmitic acid, 
gingerol, santalol, piperine and andrographolide in the selected formulation suggesting the 
presence of few ingredients such as Andrographis, Vettiver, Ginger, Santalum album and 
Pepper. Some of the anti-diabetic molecules such as vettiveric acid, piperine and 
andrographolide were also identified in the GC-MS analysis. 
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6.7 FTIR spectrum of the Nilavembu Kudineer 
 
Characteristic peaks were observed at 3406
cm-1 
indicates presents of alcohols and 
amines as these compounds show a conspicuous OH or NH stretching absorption at 3000-
3700
cm-1
 (to the left of the hydrocarbon CH stretch). This suggests presence of amines in the 
sample. 
A peak at 1155.61
cm-1 
is suggestive of presence of C-O stretch. A peak at 1640.68
cm-1
 indicates 
carbonyl (C=O) stretch. A peak at 2925.38
cm-1
 indicates CH stretch peak at 1377.94
cm-1
 
indicates Methyl C-H asym./sym. Bend of the compounds present in the sample. Peak at 
1029.45
cm-1
 indicates presence of C-N bond. Peak at 764.41
cm-1
 indicates the presence of 
mono-substituted benzene ring.  
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Sharp peaks at various position as given below indicate presence of bonds as specified 
which could be used as finger printing for the preparation:   
Table:14 FTIR Analysis 
Position Bond 
764.41
cm-1
 Disubstituted benzene ring 
1029.45
cm-1
 Primary amine,CN stretch 
1155.61
cm-1
 Amine based 
1377.94
cm-1
 Methyl C-H asym./sym 
1640.68
cm-1
 C=C stretch 
2925.38
cm-1
 Methylene CH stretch 
3406
cm-1
 Hydroxyl group,OH stretch 
 
6.8 HEAVY METAL ANALYSIS 
Table: 15 Heavy Metal Analysis 
Element 
Units in 
ppm 
Permissible 
level(ppm) 
Pb BDL 10 
Hg BDL 1 
As BDL 10 
Cd BDL 0.3 
 
 
Heavy metal analysis revealed that heavy metals like Pb, Hg, As and Cd were present in 
permissible limits  
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6,9 Microbial Analysis 
Table:16   Total Microbial Count for Nilavembu Kudineer 
 
S.No 
Bacterial 
Name 
W.H.O. 
Limit 
Cells in 
Sample/g 
Interference 
1. E.coli 10
2
 10 X 10
2
 Within Limit 
2. Salmonella sp. Absence - Within Limit 
3. Shigella sp. Absence - Within Limit 
4. 
Enterobacteria 
sp. 
10
4
 - Within Limit 
5. 
Total 
Heterotrophic 
Bacteria 
10
7
 112 X 10
4
 Within Limit 
6. 
Yeast and 
Mould 
10
4
 19 x 10
1
 Within Limit 
 
Microbial analysis suggested that the drug is free from microbial contamination 
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6.10 XRF Analysis 
 
Elemental form of various metals and minerals detected were given in Table 17 
 
 
Table: 17 XRF Analysis 
                                    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formula 
Concentration 
(%) 
K 48.34 
Ca 18.11 
Cl 17.76 
Mg 3.94 
Si 3.54 
S 2.07 
P 1.74 
Fe 1.47 
Al 0.96 
Na 0.68 
Pb 0.62 
Ti 0.18 
Mn 0.16 
Cu 0.14 
Pd 0.11 
Zn 0.09 
Mo 0.05 
Sr 0.03 
Zr 48 PPM 
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92
94
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110
10 mg/ml 5 mg/ml 2.5 mg/ml 1.25 mg/ml 0.625 
mg/ml
0 mg/ml 
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Concentration of the extract
Evaluation of cytotoxicity of aqueous extract of Nilavembu
Kudineer
6.11 In vitro studies 
In vitro cytotoxicity studies: 
Result 
Based on the results obtained from the present study, the aqueous extract of Nilavembu 
Kudineer was not toxic at a concentration range of 0.625 – 10 mg/ml in cell line model. 
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Cytotoxicity of aqueous extract of 
Nilavembu 
   Table:18Cell viability(MMTassay) 
    
 
Extract conc (mg/ml) Control 
Rep 10 5 2.5 1.25 0.625 0 
A 0.147 0.151 0.165 0.167 0.163 0.171 
B 0.156 0.146 0.153 0.168 0.172 0.169 
C 0.141 0.142 0.164 0.163 0.169 0.161 
D 0.157 0.160 0.154 0.156 0.166 0.189 
E 0.165 0.159 0.152 0.173 0.171 0.103 
F 0.157 0.165 0.156 0.154 0.162 0.164 
G 0.133 0.142 0.157 0.149 0.151 0.108 
H 0.149 0.157 0.160 0.167 0.169 0.165 
Avg 0.151 0.153 0.158 0.162 0.165 0.154 
SD 0.010 0.009 0.005 0.008 0.007 0.031 
Cell viability 
(%) 97.967 99.350 102.520 105.447 107.561 100.000 
 
 
Based on the data obtained in the in vitro cytotoxicity studied it is concluded that the 
aqueous extract of Nilavembu Kudineer is not toxic at a concentration range of 0.625 – 10 
mg/ml in cell line model.  
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6.12 PRE CLINICAL STUDIES 
Acute oral toxicity study 
Mortality 
 No mortality was recorded (Table 19). 
Body Weight 
 The animals treated with Nilavembu Kudineer did not show any significant change in 
body weight gain on day 7 and 14 when compared with Day 0. (Table 20). 
Feed Intake 
 The daily feed intake of rats remained unaffected throughout the experimental period 
(Table 21). 
 
Toxicity Signs 
 No visible signs of toxicity such as changes in respiration, circulation, autonomic and 
central nervous system, behavioral pattern were observed during the entire study period.  
(Table 22). 
 
Gross Pathology 
No test compound related findings were observed at necropsy. All gross observations 
were agonal in nature and bore no relation to treatment with the test substance (Table 23). All 
animals survived until the end of study. 
 
Results  
Table: 19 Mortality Data 
 
Details of the Group 
 
Total no. of 
rats treated 
 
Dose 
(mg/kgb.w.) 
Percent mortality 
(upto 14 days) 
Nilavembu Kudineer treated 5 Female 2000 0 
b.w. - Body Weight. 
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Table: 20 Weekly Mean Body Weight Changes In Rats 
Animal ID Sex 
Body Weight (g) 
Day 0 Day 7 Day 14 
6022 Female 183.22 186.99 190.01 
6023 Female 171.07 175.23 177.93 
6024 Female 174.02 184.47 188.29 
6025 Female 169.82 173.08 174.20 
6026 Female 178.06 182.64 188.10 
Mean 175.24 180.48 183.71 
Standard deviation 5.47 6.03 7.14 
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Table: 21 Daily Feed Intake  
 
 
Animal  
ID 
 
Sex 
Days 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 
6022 F 16.76 17.09 18.28 15.23 19.13 16.83 16.02 15.98 16.43 13.97 17.97 15.14 16.00 15.83 
6023 F 16.95 16.32 21.03 16.98 17.54 14.74 18.39 15.88 18.41 15.70 17.26 16.47 17.94 17.63 
6024 F 17.57 14.91 19.33 15.30 19.29 15.53 14.55 12.15 18.27 16.55 16.47 15.29 17.28 17.32 
6025 F 16.37 15.96 18.15 15.82 17.04 15.05 18.89 16.19 18.30 16.29 16.76 16.50 16.30 16.97 
6026 F 17.46 14.32 20.33 15.72 19.75 17.24 18.63 14.96 18.88 17.36 15.46 17.41 16.02 18.36 
Mean 17.02 15.72 19.42 15.81 18.55 15.88 17.30 15.03 18.06 15.97 16.78 16.16 16.71 17.22 
SD 0.50 1.11 1.26 0.70 1.19 1.10 1.92 1.68 0.94 1.27 0.93 0.94 0.86 0.93 
 
M - Male;    F- Female; SD – Standard deviation; 
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Table: 22 Toxicity signs observed in Female Rats 
Observation* Days 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Appeared Normal 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 
Found death 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Catalepsy 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Chromodacryorrhea 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Clonic 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Coma 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Convulsion 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Diarrhea 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Dullness 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Excessive grooming 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Change in Gait 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Hyperactivity 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Lacrimation 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Nasal discharge 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Nasal irritation 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Piloerection 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Polyuria 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Prostration 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Repetitive circling 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Respiratory distress 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Salivation 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Tonic 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Tremor 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Uro-genital staining 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
* No. of animals showing the clinical sign / No. of animals per group
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Table:23 Gross Pathology 
 
 
S. No. 
 
Sex 
 
Animal 
No. 
Status of 
The animal at the time 
of receipt at necropsy 
 
Lesions observed at 
necropsy 
1 F 6022 Live NAD 
2 F 6023 Live NAD 
3 F 6024 Live NAD 
4 F 6025 Live NAD 
5 F 6026 Live NAD 
 
 
F–Female; NAD- No Abnormalities Detected 
 
 Acute oral toxicity studies on aqueous extract of Nilavembu Kudineer showed no 
mortality in rats at doses up to 2 g/kg. There were no toxicity signs observed on the skin, fur 
or eyes of the animals.  
From the present study, it is concluded that the Nilavembu Kudineer is non-toxic upto 
2000 mg/kg body weight of oral administration and no significant toxic symptoms were 
observed during the observation period as well as post mortem examination. 
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Results-Pharmacological activity 
 
Table: 24 Effect of Nilavembu Kudineer on blood glucose against STZ induced diabetic 
rats 
Groups 
Blood Glucose level (mg/dl) 
Day 0 Day 7 Day 14 Day 21 Day 28 
Normal 
control 
75.38±1.39 75.63±0.53 81.25±1.40 78.25±1.32 58.13±1.47 
Diseased 
control 
489.30±40.09z 482.90±44.82z 494.30±32.24z 511.90±26.90z 421.10±27.72z 
Metformin  
(100 mg/kg, 
p.o) 
453.30±27.93z 402.50±18.07z 370.90±15.36z,c 336.50±15.94z,c 244.50±8.43c,z 
Nilavembu 
Kudineer 
(100 mg/kg, 
p.o) 
492.60±10.17z 425.70±21.83z 438.00±18.87z 426.70±13.43a,z 314.70±23.86b,z 
Nilavembu 
Kudineer 
(200 mg/kg, 
p.o) 
426.70±37.53z 380.80±20.14z 380.00±20.84b,z 337.00±13.46c,z 279.00±11.75c,z 
Nilavembu 
Kudineer 
(400 mg/kg, 
p.o) 
464.00±25.23z 417.40±23.15z 353.90±17.72c,z 332.60±15.33c,z 274.40±17.63c,z 
 
Values represented as mean±SEM, n=6, 
z
P<0.001, 
y
P<0.01, 
x
P<0.05 compared with normal 
control, 
c
P<0.001, 
b
P<0.01, 
a
P<0.05 compared with diseased control,   
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The anti diabetic effect of Nilavembu Kudineer evaluated at different dose levels 100, 
200 and 400 mg/kg and compared using a positive control in STZ induced hyperglycemia rats 
are presented in the table: 24. Hyperglycemia was induced by single intrapertoneal injection 
of streptozotocin and significant 
(
P<0.001) increase in blood glucose level was noticed after 
48 hours in all rats induced with single injection. The diabetic rats were administered with 
standard drug (Metformin 100 mg/kg) and three different doses of Nilavembu Kudineer (100, 
200 and 400 mg/kg) were administered orally for a period of 28 days. 
 
 Metformin at the dose 100 mg/kg showed significant (P<0.001) decrease in blood 
glucose level on Day 14 of the drug treatment, where as Nilavembu Kudineer at the dose 
level 200 and 400 mg/kg also showed significant (P<0.05) decrease in glucose levels in STZ 
induced diabetic rats. The extract at low dose (100 mg/kg) did not produce any significant 
(P>0.05) decrease in blood glucose level in diabetic rats. 
   
On Day 21, diabetic rats treated with low dose of Nilavembu Kudineer (100 mg/kg) 
also showed significant (P>0.05) decrease in blood glucose level as compared with disease 
control.  
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Table: 25 Effect of Nilavembu Kudineer on serum biochemical parameters in Diabetic 
rats 
Groups 
Glucose 
(mg/dl) 
TGL 
(mg/dl) 
Total 
Cholesterol 
(mg/dl) 
Urea 
(mg/dl) 
Creati-
nine 
(mg/dl) 
Total 
protein 
(g/dl) 
Albu-
min 
(g/dl) 
Normal 
control 
71.00 
±4.62 
32.86 
±2.79 
60.50 
±3.59 
39.98 
±1.78 
0.48 
±0.01 
5.90 
±0.10 
2.77 
±0.06 
Diseased 
control 
404.00 
±33.76c 
68.50 
±14.52a 
51.75 
±2.85 
68.73 
±5.32c 
0.53 
±0.01a 
5.57 
±0.07 
2.72 
±0.11 
Metformin 
(100 mg/kg, 
p.o) 
163.50 
±26.04z 
43.50 
±2.60 
52.00 
±3.84 
50.76 
±2.61 
0.51 
±0.01 
5.75 
±0.19 
2.49 
±0.14 
Nilavembu 
kudineer 
(100 mg/kg, 
p.o) 
428.90 
±33.77 
69.57 
±10.25 
55.75 
±4.59 
59.76 
±6.69 
0.50 
±0.01 
5.94 
±0.15 
2.61 
±0.12 
Nilavembu 
kudineer 
(200 mg/kg, 
p.o) 
255.80 
±53.55x 
70.88 
±6.13 
57.63 
±3.23 
46.28 
±3.65x 
0.46 
±0.01y 
5.93 
±0.17 
2.91 
±0.14 
Nilavembu 
kudineer 
(400 mg/kg, 
p.o) 
143.00 
±19.93z 
66.00 
±6.50 
60.14 
±4.18 
45.51 
±4.80y 
0.45 
±0.02z 
6.17 
±0.07x 
2.75 
±0.15 
 
Values represented as mean±SEM, n=6, 
c
P<0.001, 
b
P<0.01, 
a
P<0.05 compared with 
normal control, 
z
P<0.001, 
y
P<0.01, 
x
P<0.05 compared with diseased control,  
 
After 28 days of drug treatment, all the fasted rats were subjected to blood collection; 
the serum separated was subjected to biochemical analysis. Serum glucose level in STZ 
induced rats showed significant (P<0.001) increase when compared with normal control rats. 
The diabetic rats treated with metformin at the dose level 100 mg/kg for 28 days revealed 
significant (P<0.001) decrease in serum glucose levels. Whereas 200 and 400 mg/kg 
Nilavembu Kudineer treated diabetic rats showed significant (P<0.001) decrease in serum 
glucose level. 
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In STZ induced diabetic rats, a significant (P<0.05) increase in serum triglycerides 
levels was observed (68.50±14.52) when compared to normal (32.86±2.79). The diabetic rats 
treated with reference drug, metformin showed decrease trend in serum triglycerides when 
compared with STZ induced diabetic rats. Similar trend was also observed in diabetic rats 
treated orally with Nilavembu Kudineer at the dose level 400 mg/kg. 
 
Serum urea level in STZ induced diabetic rats showed significant (P<0.001) increase 
compared with normal control rats. The diabetic rats treated with Nilavembu Kudineer at the 
dose levels 200 and 400 mg/kg revealed significant (P<0.05) decrease in serum urea level 
compared with STZ induced diabetic rats. Similarly, Serum creatinine level in STZ induced 
diabetic rats showed significant (P<0.05) increase compared with normal control rats. The 
diabetic rats treated with Nilavembu Kudineer at the dose levels 200 and 400 mg/kg revealed 
significant (P<0.01) decrease in serum creatinine level compared with STZ induced diabetic 
rats. 
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Table: 26 Effect of Nilavembu Kudineer on body weight in STZ induced diabetic rats 
Groups 
Weekly body weight (Grams) 
Before 
STZ 
induction 
Day 0 Day 7 Day 14 Day 21 Day 28 
Normal 
control 
178.4 
±5.09 
195 
±4.97 
212.9 
±4.96 
220.5 
±5.36 
225.5 
±5.56 
220.7 
±6.09 
Diseased control 
182.7 
±8.28 
175.3 
±7.97 
158 
±9.54 
162.8 
±9.18 
156.5 
±10.87 
157.3 
±11.16 
Metformin  
(100 mg/kg, p.o) 
175.3 
±7.79 
168.9 
±8.67 
151.6 
±8.25 
155.4 
±7.97 
161.4 
±7.06 
154.8 
±8.60 
Nilavembu Kudineer 
(100 mg/kg, p.o) 
178 
±4.18 
170 
±4.66 
155.4 
±7.17 
156.2 
±9.88 
172 
±8.89 
159.3 
±9.28 
Nilavembu Kudineer 
(200 mg/kg, p.o) 
185.7 
±4.28 
178.1 
±4.04 
161.3 
±6.30 
163.6 
±7.92 
164.9 
±8.17 
161.8 
±8.50 
Nilavembu Kudineer 
(400 mg/kg, p.o) 
176.7 
±4.77 
168.4 
±6.73 
151.7 
±10.39 
155.9 
±10.58 
154.3 
±11.89 
145.7 
±12.79 
 
Values represented as mean±SEM, n=6  
 
The weekly body weight changes of different groups of rats are given in table 5. It 
was observed that there were no significant changes in body weight in diabetic rats treated 
with Nilavembu Kudineer when compared with STZ treated rats throughout the entire period 
of drug treatment.  
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Table: 27 Effect of Nilavembu Kudineer on feed and water intake and urine 
output in STZ induced diabetic rats 
Groups 
Feed intake 
(g/rat/day) 
Water intake 
(ml/rat/day) 
Urine output 
(ml/rat/day) 
Normal 
control 
26.1±2.4 38.3±1.7 10.3±0.3 
Diseased control 74.3±4.1c 126.7±12.0c 113.3±8.8c 
Metformin  
(100 mg/kg, p.o) 
42.8±4.3y 120.0±5.8 86.7±8.8 
Nilavembu Kudineer  
(100 mg/kg, p.o) 
56.9±4.5 126.7±6.7 98.3±10.9 
Nilavembu Kudineer  
 (200 mg/kg, p.o) 
50.6±2.4x 111.7±10.1 75.0±8.7x 
Nilavembu Kudineer  
 (400 mg/kg, p.o)  
46.5±5.0y 88.3±6.0x 48.3±6.0y 
 
Values represented as mean±SEM, n=3, 
c
P<0.001, 
b
P<0.01, 
a
P<0.05 compared with normal 
control, 
z
P<0.001, 
y
P<0.01, 
x
P<0.05 compared with diseased control 
 
Feed intake, water intake and urine output were measured using metabolic cages and 
the values were tabulated. Feed intake, water intake and urine output was measured during 4
th
 
week of drug administration in STZ induced diabetic rats. All the diabetic rats showed 
significant (P<0.001) increase in feed intake, water intake and urine output when compared 
with normal rats.  Diabetic rats treated with extract for 28 days were able to produce 
significant (P<0.001) decrease in water consumption and urine output, when compared with 
STZ induced diabetic rats. 
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Histopathological findings of liver, Kidney and pancreas in Nilavembu Kudineer treated 
diabetic rats are photo-micrographed and presented in sequel. 
LIVER 
 
Fig-12 CONTROL 
Within normal limits 
 
 
 
 
Fig-13 DISEASE CONTROL 
 
Infiltrates, mononuclear, peribiliary/parenchymal, diffuse, mild 
Microgranuloma, multiple, random, minimal 
Necrosis, hepatocellular, multifocal, random, minimal 
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Fig-14 STANDARD 
Atrophy, hepatocellular, diffuse, minimal 
 
 
 
 
 
Fig-15 LOW DOSE 
Infiltrates, mononuclear, peribiliary/parenchymal, diffuse, mild 
Microgranuloma, multiple, random, mild 
Necrosis, hepatocellular, multifocal, random, mild 
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Fig-16 MEDIUM DOSE 
Within normal limits 
 
 
 
 
Fig-17 HIGH DOSE 
Infiltrates, mononuclear, peribiliary/parenchymal, diffuse, minimal 
Microgranuloma, multiple, random, minimal 
Necrosis, hepatocellular, multifocal, random, minimal 
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Fig-18 CONTROL (Kidney) 
 
Infiltrates, mononuclear, interstitial, multifocal, minimal 
 
 
Fig-19 DISEASE CONTROL(Kidney) 
Vacuolation/ degeneration, tubular, diffuse, mild 
Infiltrates, mononuclear, interstitial, multifocal, mild 
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Fig-20 STANDARD(Kidney) 
Vacuolation/ degeneration, tubular, diffuse, mild 
 
 
 
 
Fig-21 LOW DOSE(Kidney) 
 
Vacuolation/ degeneration, tubular, diffuse, minimal 
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Fig-22 MEDIUM DOSE(Kidney) 
 
Vacuolation/ degeneration, tubular, diffuse, mild 
 
 
 
 
Fig-23 HIGH DOSE(Kidney) 
 
Vacuolation/ degeneration, tubular, diffuse, mild 
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Fig-24 CONTROL (Pancreas) 
Within normal limits 
 
 
 
Fig-25 DISEASE CONTROL(Pancreas) 
 
Atrophy / degeneration, Islet cells, diffuse, marked  
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Fig-26 STANDARD(Pancreas) 
Atrophy / degeneration, Islet cells, diffuse, minimal 
 
 
Fig-27 LOW DOSE(Pancreas) 
Atrophy / degeneration, Islet cells, diffuse, minimal 
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Fig-28 MEDIUM DOSE(Pancreas) 
Atrophy / degeneration, Islet cells, diffuse, mild 
 
 
Fig-29 HIGH DOSE(Pancreas) 
Atrophy / degeneration, Islet cells, diffuse, mild 
From the photomicrographs of histopathological studies, it is inferred that altered 
cellular architecture observed in the liver, kidney and pancreas of diabetic rats were brought 
back to near normalcy on administration of Nilavembu Kudineer. 
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6.13 Clinical trial studies  
 
 Total number of patients screened         90  
 No. of Patients selected for the study    60 
 No. of dropped out                                 12 
 No. of cases participated throughout      
the study period                                     48 
 
Table: 28 Socio-demographic Features  
 
Diabetic  Studies Male Female 
No. of Cases 26 22 
Age 30-44 30-59 
Locality Rural  16 10 
Urban  12 10 
Dietary Habit Veg. 6 8 
Mixed Diet. 20 14 
Smoking/Tobacco 
Consumption 
8 5 
Economic Status Low  7 5 
Middle  12 9 
High  7 8 
Educational Status Literate 21 14 
Illiterate 5 8 
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Table:29 Naa (Tongue) observations  
 
 
Observations 
 
Before Treatment  
 
After Treatment  
Pale 22 18 
Coating 10 8 
Dryness 21 20 
Redness 3 2 
Fissures in margin 0 0 
Alteration in taste 15 10 
Alteration in teeth and gums 20 17 
Normal 20 20 
 
Table: 30 Body Constitutions 
 
S. No Constitution of  the body No. of cases 
1. Vatha Thegi  10 
2. Pitha Thegi   22 
3. Kapha Thegi 6 
4. Thontha Thegi  10 
 
Table:31 Distribution of Season 
S. No Season No. of cases 
1. Kaar Kaalam 6 
2. Koothir Kaalam 3 
3. Munpani Kaalam 15 
4. Pinpani kaalam 8 
5. Ilaveni Kaalam 10 
6. Muthuveni Kaalam 6 
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Table:32 Distribution of Uyir Thathukkal 
Uyir Thathukkal Before treatment After  treatment 
Vatham 
Pranan 22 17 
Abanan 38 26 
Viyanan 22 18 
Udhanan 20 15 
Samanan 17 12 
Nagan 9 7 
Koorman 8 6 
Kirukaran 5 3 
Devathathan 22 11 
Dhananjeyan 15 12 
Pitham 
Anarpitham 26 23 
Ranjaga Pitham 15 12 
Prsaka Pitham 18 14 
Alosaga Pitham 19 15 
Sathaga Pitham 22 11 
Kabham 
Avalam bagam 10 23 
Kilethagam 22 12 
Pothagam 28 12 
Tharpagam 12 11 
Santhigam 28 21 
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Table: 33 Distribution of Status of Envagai Thervugal  
Envagai Thervu Affected Thathu Before 
treatment 
After  
treatment 
Naa Vatha kuttram 12 10 
 Pithakuttram 22 21 
 Kabhakuttram 4 2 
 Iyalbu(normal) 10 10 
Niram Vatha kuttram 5 2 
 Pithakuttram 6 5 
 Kabhakuttram 3 2 
 Iyalbu(normal) 34 34 
Mozhi Vatha kuttram 4 2 
 Pithakuttram 5 4 
 Kabhakuttram 2 1 
 Iyalbu(normal) 37 37 
Vizhi Vatha kuttram 11 9 
 Pithakuttram 18 14 
 Kabhakuttram 5 3 
 Iyalbu(normal) 14 14 
Sparism Vatha kuttram 4 3 
 Pithakuttram 6 3 
 Kabhakuttram 2 1 
 Iyalbu(normal) 36 36 
Moothiram Vatha kuttram 12 8 
 Pithakuttram 24 18 
 Kabhakuttram 8 6 
 Iyalbu(normal) 4 4 
Malam Vatha kuttram 12 10 
 Pithakuttram 22 17 
 Kabhakuttram 8 4 
 Iyalbu(normal) 4 3 
Naddi Vatha kuttram 8 6 
 Pithakuttram 24 20 
 Kabhakuttram 6 3 
 Iyalbu(normal) 10 10 
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Table: 34 Involvement of Ezhu Udalkattugal (Seven Body Constituents) 
 
S. No Udalkattugal No. of cases percentage 
1. Saaram – Serum 30 62 
2. Senneer – Blood 48 100 
3. Oon – Muscle 22 46 
4. Kozhuppu – Fat 12 27 
5. Enbu – Bone 2 4.6 
6 Moolai – Brain 2 4 
7. Sukkilam/Suronitham 
– Semen/ovum 
5 11 
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Table:35 Evaluation of effect of Nilavembu Kudineer on Hemopoetic function 
 
Parameters 
Normal Range Before 
Treatment 
After 
Treatment 
Lymphocytes (%) 
20-45 29.72 
±4.28 
28.82 
±4.73 
Eosinophils (%) 
01-06 5.42 
±1.24 
4.29 
±1.37 
Platelet count 
(lacs/cumm) 
1.5-4.0 2.38 
±0.63 
2.55 
±0.47 
Hb (g/dL) 
 
M-12-17 
F 12-15 
12.9±1.89 12.9±1.48 
 
     Table:36 Evaluation of effect of Nilavembu Kudineer on Liver function 
 
Parameters 
Normal 
Range 
Before 
Treatment 
After 
Treatment 
Serum billirubin 
(mg/dl) 
0.3-1.0 0.63 
±0.18 
0.60 
±0.18 
Total protein 
(gm /dl) 
6.0-8.5 6.52 
±1.26 
6.60 
±1.36 
Albumin 
(gm/dl) 
3.5-5.0 3.69 
±1.38 
3.40 
±1.30 
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 Table:37  Data on Renal function test following Nilavembu Kudineer therapy 
 
Factors Normal 
Range 
Before 
Treatment 
After 
Treatment 
Blood Urea (mg/dL) 
 
10-50 
24±3.95 23.5±3.52 
Serum Creatinine  
(mg/dL) 
 
M 0.9-1.3 
F 0.6-1.1 0.77±0.15 0.77±0.25 
 
Table:38 Effect of Nilavembu Kudineer on Lipids 
Treatment group Normal Range 
Before 
Treatment 
After 
Treatment 
Triglycerides 
 
< 170 mg/dL 
 
134±29.7 137±30.9 
Serum 
Cholesterol  
 
Upto 200 mg/Dl 178±22.1 176±21.4 
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Table:39 Effect of Nilavembu Kudineer on Fasting and Post Prandial Blood Glucose 
 
Treatment group 
Normal 
Range 
0 Day 
30 days 
45days 60 days 
90 days 
Fasting Blood 
Glucose 
           (mg/dL) 
70 – 110  
129 
± 
11.7 
126 
± 
11.3 
124 
± 
12.3 
123 
± 
12.3 
122 
± 
10.8 
Post prandial  
Blood Glucose 
   (mg/dL) 
 
80 – 140  
221± 
22.3 
219 
± 
25.0 
215 
± 
27.0 
214 
± 
27.0 
208 
± 
27.7 
HbA1c (%) 
 
< 6.5 % 8.35±0.
62 
- - - 
7.75±0.9
0 
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Findings  
The diagnosis and prognosis was done on the basis of all the above mentioned Siddha 
and modern parameters and the results are summarized below. 
Out of the 60 subjects selected, 15 cases dropped out in the middle of the study and 
only 48 (22 females, 26 males) cases cooperated till the end of the study. 
  
Clinical observations 
 6 subjects showed vatha naadi, 38 subjects showed pithta naadi and 4 subjects showed kapha 
and thontha naadi.  
 Based on body proportion 22 pitha subjects, 16 kapha subjects and 10 vatha subjects were 
identified. Among this, pitha and kapha people showed marked improvement whereas vaatha 
people showed only symptomatic improvement  
 Disorientation of pitha was found in 38 patients out of which 28 recovered. 2 of the 4 subjects 
with kapha disorientation, and 3 out of 6 subjects with vatha disorientation also recovered to 
normal. This indicates that this plant was more effective in treating pitha  dominated 
diabetic complications as compared to vatha and kapha dominated complications.    
 Significant changes in fasting blood sugar were noted only in 28 patients  
 But 25 subjects showed significant improvement in post prandial glycemic level after 
treatment.  
 Glycated hemoglobin markedly reduced in 20 patients    
 Most of the subjects reported reduction in excessive appetite, which is the most common 
symptom of Type II Diabetes. 
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CHAPTER – VII 
DISCUSSION 
7.1 DISCUSSION 
In the past decades, diabetes mellitus has become a major health problem world wide, 
reaching epidemic proportions in many developing countries including India. World wide 
projections suggest that >220 million people will have diabetes by the year 2020 and 
majority of these (approximately 213 million) will have type-II diabetes. Recently Diabetes 
mellitus has emerged as a leading metabolic disorder. India is the diabetic capital of the 
world, with 41 million people affected with the disease. 
In spite of greater advancements made in understanding and managing this disease, 
the graph of diabetes-related complications and mortality are rising unabatedly.  With an 
objective of identifying a safe and novel anti-diabetic drug from traditional medicinal 
sources, Siddha drug Nilavembu Kudineer is selected for the present study and evaluated for 
its anti-diabetic and toxicity profiles employing Streptozotocin (STZ) induced diabetic rats.  
The selected drug is also assessed for its clinical efficacy in Type 2 diabetes mellitus 
patients. Besides the selected Siddha herbal formulation is also studied from chemical and 
botanical standardization point of view in order to contribute to the suffering diabetic 
population a quality standard anti diabetic Siddha herbal drug. 
7.2 Botanical studies: Powder microscopic analysis of the preparation 
Powder microscopy of Nilavembu Kudineer revealed the presence of all the 
ingredients mentioned in the Siddha text. The unique microscopic features of the ingredients 
of Nilavembu Kudineer were compared with the microscopic characters which are 
mentioned in the Siddha Pharmacopoeia and other literatures were compared with given 
curnam. 
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7.2.1Botanical standards determined 
Based on the powder microscopy following botanical standards were determined for 
the Nilavembu Kudineer: 
 Wavy epidermal cells  
 Sclerenchyma cells with narrow lumen 
 Vessels with simple pits and scalariform thickening, parenchyma cells with reticulation 
 Tracheids are thick walled 
 Fibres with branching and split ends, libriform, thin walled, with tapering end wide 
lumen  
 Polygonal cork cells 
 Presence of tricolpate pollen grains and group of fibres and brown content, slightly 
elongated and beaker shaped stone cells  
 Presence of unicellular and short and long uniseriate trichomes with bi and tri cellular, 
short and long uniseriate multicellular headed glandular trichome 
 Presence of stone cells and various shaped and striated sclereids 
 Starch grains round to oval calcium oxalate crystals prismatic and acicular  
 
7.3 Chemical standardization studies:  
Physico chemical constants were determined as per the standard siddha pharmacopoeia  
  
Chemical standards 
Based on the studies following chemical standards for identity, purity and strength 
were determined for Nilavembu Kudineer.  
Test for identity, purity and strength 
 pH not more than 7  
 Loss on drying not more than 6%  
 Total ash not more than 31% 
 Acid insoluble ash not more than 2%  
 Alcohol soluble extractives not less than 4%  
 Water soluble extractives not less than 81%  
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Preliminary phytochemical screening 
Preliminary phytochemical screening revealed the presence of various bioactive 
compounds like alkaloids, sterols, terpenoids, saponins, carbohydrates and mucilage in 
Nilavembu Kudineer. The tests for flavonoids, tannins and phenols gave negative results, 
which indicated their absence in Nilavembu Kudineer.   
 
7.4 HPTLC Finger printing studies 
The HPTLC analysis of Nilavembu Kudineer revealed the presence of 11 spots with 
Rf at 0.31, 0.55, 0.58, 0.65, 0.70, 0.77, 0.82, 0.88, 0.92, 0.95 and 0.97 under 254 and 366 nm. 
The Rf value 0.70 indicates the presence of Andrographolide, the marker compound.  
 
7.5 GC-MS studies 
The GC-MS analysis of Nilavembu Kudineer showed the presence of vetiveric acid, 
palmitic acid, gingerol, santalol, piperine and andrographolide in the selected formulation 
suggesting the presence of few ingredients such as Andrographis, Vettiver, Ginger, 
Santalumalbum and Pepper. Some of the anti-diabetic molecules such as vettiveric acid, 
piperine and andrographolide were also identified in the GC-MS analysis.  
FTIR analysis of Nilavembu Kudineer revealed the presence of alkanes, amine, 
carboxylic, hydroxyl and aromatic functional groups. 
 
7.6 In vitro cytotoxicity 
The aqueous extract was prepared by taking 25 g of Nilavembu Kudineer raw 
material in 500 ml of distilled water and boiled at 90°C until the final volume reaches to 100 
ml. Then the content was filtered and the filtrate was frozen and then lyophilized. The extract 
yield was found to be 1.32 g/100 g drug. The extract was re-suspended in water at 10 mg/ml 
ratio and used for the cytotoxicity experiment. For evaluating cytotoxicity 3T3-L1 pre-
adipocytes were obtained from the National Center for Cell Science (NCCS), Pune and 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine 
serum (FBS) and penicillin (100 U/mL)-streptomycin (100 μg/mL) in a humidified 
atmosphere of 95% air and 5% CO2 at 37°C. After arriving 60% of confluency, the cells were 
trypsinized and dispersed in a 96 well plate with a cell count of 9000 cells per well and 
incubated for 24 h. Then the aqueous extract of the selected formulation was added at 
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different concentrations (10, 5, 2.5, 1.25 and 0.625 mg/ml) and then again incubated for 24 h. 
The cell group grown in medium without plant extract was considered as control. At the end, 
the medium was discarded, cells are washed with PBS and then MTT reagent (20 µL) was 
added in each well and incubated for 6 hrs at 37
°
C in a water bath. Then 150 µL of acidic 
isopropanol was added and shaken for 30 min on a plate shaker under dark. The absorbance 
was measured at 540 nm in a micro-plate reader and the cell viability was calculated and 
expressed in percentage basis. Based on the data obtained in the present study, it is concluded 
that the aqueous extract of Nilavembu kudineer is not toxic at a concentration range of 0.625 
– 10 mg/ml in cell line model. 
 
7.7 Acute oral toxicity 
Acute oral toxicity study was performed for aqueous extract of Nilavembu Kudineer 
as per OECD 425 guideline (OECD, 2008). All procedures involving laboratory animal use 
were in accordance with the Institute Animal Ethics Committee regulations approved by the 
Committee for the Purpose of Control and Supervision of Experiments on Animals 
(CPCSEA) and the approval number is 357/SASTRA/IAEC/RPP. Healthy Female Albino 
Wistar rats were selected for the studies and administered with a single oral dose of aqueous 
extract of Nilavembu Kudineer at the dose of 2000 mg/kg, b.wt by oral route dissolved in 1 
mL of distilled water used as the vehicle. Each animal was observed for every 15 min in the 
first 4 h after dosing, then every 30 min for the successive 6 h and then daily for the 
successive 48 h for the short-term outcome and the remaining 14 days for the long-term 
possible lethal outcome which in this case was death. The animals were observed for signs of 
convulsions, tremors, circling, depression, excitement and mortality. The surviving animals 
were sacrificed under CO2 inhalation euthanasia, autopsied and examined macroscopically 
for any pathological changes. Acute oral toxicity studies of aqueous extract of Nilavembu 
Kudineer showed no mortality in rats at doses up to 2 g/kg. There were no toxicity signs 
observed on the skin, fur or eyes of the animals. No noticeable behavioral changes in 
salivation, sleeping pattern, diarrhea or lethargy were observed in the treated animals. These 
results indicate that aqueous extract of Nilavembu Kudineer is non-toxic, and safe up to 2 
g/kg, b. wt. through oral route. 
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7.7.1Anti-diabetic activity 
Anti-diabetic screening of aqueous extract of Nilavembu Kudineer against 
Streptozotocin (STZ)-Induced Diabetics in Rats was conducted. Male Albino Wistar rats were 
used for screening anti-diabetic potential of the selected formulation. Diabetes was induced 
by a single intraperitoneal injection of Streptozotocin (STZ, 65 mg/kg) dissolved in 0.1 M 
citrate buffer (pH 4.5) in fasted rats. The control group rats were administered with distilled 
water. The Diabetes was confirmed at 48 h after STZ injection by measuring the glucose 
concentrations of peripheral blood obtained from the tail vein using glucometer. Rats with 
blood glucose levels of 250 mg/dl or higher were considered to be diabetic and were grouped 
into six groups each containing eight rats. The diabetic induced rats were treated with 
vehicle/standard/test drug orally as per the study protocol for 4 weeks. The change in body 
weights and blood glucose level were measured weekly. During the last week of drug 
treatment, experimental animals were housed in metabolic cages and the changes in feed 
intake, water intake and urine output were measured and calculated.  At the end of the 
experiment, all the rats were fasted overnight and blood samples were collected by retro 
orbital puncture under mild anesthesia. The blood samples were collected in serum activator 
tubes and centrifuged at 1000 g for 15 min to obtain serum. The serum layer was collected in 
properly labeled, clean and micro-centrifuge tubes and analyzed immediately for biochemical 
parameters such as total protein, total cholesterol and triglycerides levels. For 
histopathological study, pancreas, liver and kidney tissues were collected and fixed in 10% 
buffered formalin solution. After a minimum of 24 hour fixation, the samples were stained 
using Hematoxylin and eosin. They were examined under a light and polarized microscope. 
All deviations from normal histology were recorded and compared with the corresponding 
controls.  
 
Streptozotocin (STZ) is widely used experimentally to induce diabetes in animals 
(Zusman et al., 1985). STZ after uptake into pancreatic beta cells, is split up into glucose and 
methylnitrourea moiety. The latter, due to its alkylating properties, modifies biological 
macromolecules, fragments of DNA and destroys the beta cells thus causing diabetes 
(Szkudelski 2001, Okamoto,1981). 
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The major symptoms of diabetes are hyperglycemia along with polyuria, polydipsia 
and polyphagia. In the present study, STZ induced rats showed three characteristic symptoms 
such as polyuria, polydipsia and polyphagia. Nilavembu Kudineer treatment for 28 days has 
brought back the above mentioned symptoms to normal. 
Decreased body weight observed in diabetic control rats in comparison to normal rats 
indicates that loss of body weight is a result of excessive breakdown of tissue proteins 
(Salahuddi et al., 2010). Kondeti et al have reported that STZ induced diabetic rats account 
for the observed decrease in the total protein content.  
 
One of the most sensitive and dramatic indicators of kidney injury is to increase the 
creatinine and urea level in serum. Increased urea production in diabetes might be due to 
enhanced catabolism of both liver and plasma proteins (Kondeti et al., 2010).  
 
The diabetic hyperglycemia induces elevation of the serum levels of urea and 
creatinine which were considered as significant markers of renal dysfunction (Almdal and 
Vilstrup, 1988). In the present study, STZ induced rats showed significant increase in the 
level of serum urea and creatinine, after treatment with Nilavembu Kudineer in diabetic rats 
for 28 days elevated serum urea and creatinine levels were found to be decreased 
significantly. The stabilization of these renal parameters by Nilavembu Kudineer suggests its 
protection against Diabetic nephropathy, which is one of the diabetic complications observed 
in chronic diabetic patients. If used as hypoglycemic agents, may also reverse dyslipedemia 
associated with diabetes and prevent the cardiovascular complications which are very 
prevalent in diabetic patients. 
 
7.8 Clinical Studies 
After the approval of Institute Human Ethical Committee, a pilot scale human clinical 
study was conducted at National Institute of Siddha, Thambaram Sanitorium, Chennai.   
In Naadi examination, pitha vatha naadi and vatha pitha naadi were found in most of 
the patients, Out of 90 patients screened, 60 patients had the positive family history of 
Diabetes mellitus, thus it approves the statement that hereditary factors influence the 
occurrence of Diabetes mellitus.  
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Selected 60 human subjects belonging to both sexes in the age group between 30 yrs 
to 60 yrs were examined for clinical symptoms and were treated as Out- Patients and were 
administered with Nilavembu Kudineer at the dose level of 60 ml once a day.  12 subjects 
dropped during the study period 48 subjects continued through out the study period. 
7.8.1 Clinical Findings  
The diagnosis and prognosis was done on the basis of all the above mentioned Siddha 
and modern parameters and the results are summarized below. 
Out of the 60 subjects selected, 12 cases dropped out in the middle of the study and 
only 48 (22 females, 26 males) cases cooperated till the end of the study. 
  
7.8.2Clinical observations 
 6 subjects showed vatha naadi, 38 subjects showed pithta naadi and 4 subjects 
showed kapha and thontha naadi.  
 Based on body proportion 22 pitha subjects, 16 kapha subjects and 10 vatha subjects 
were identified. Among this, pitha and kapha people showed marked improvement 
whereas vatha people showed only symptomatic improvement  
 Disorientation of pitha was found in 38 patients out of which 28 recovered. 2 of the 4 
subjects with kapha disorientation, and 3 out of 6 subjects with vatha disorientation 
also recovered to normal. This indicates that this plant was more effective in treating 
pitha dominated diabetic complications as compared to vatha and kapha dominated 
complications.    
 Significant changes in fasting blood sugar were observed only in 28 patients  
 30 subjects showed significant improvement in post prandial glycemic level after 
treatment.  
 Glycated hemoglobin was markedly reduced in 20 patients    
 Most of the subjects reported reduction in excessive appetite, which is the most 
common symptom of Type II Diabetes. 
 
The data of the results obtained clearly depict the anti-diabetic efficacy of Nilavembu 
Kudineer in human subjects.  
 
 
  
128 
 
To conclude the study drug, Nilavembu Kudineer is proved for its quality, both 
botanically and chemically and is found to be safe and effective in the management of type 2 
Diabetes mellitus. 
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CHAPTER VIII 
Summary and Conclusion 
8.1Summary and Conclusion 
Herbs and herbal formulations used in traditional medicines in Siddha have been 
widely accepted in India as good therapeutical agents with lower side effects particularly in 
the management of Diabetes mellitus, a metabolic disorder which is growing exponentially at 
an alarming rate. But there exist lacuna in these traditional medicines such as lack of 
standards for products as well as the processes their safety and efficacy. Hence the need of the 
hour is to scientifically validate and conduct studies on quality, safety and efficacy of these 
traditional herbal formulations. With these objectives, in the present dissertation a traditional 
Siddha formulation Nilavembu Kudineer is selected based on the literature survey and 
scientifically evaluated for its anti-diabetic efficacy through both preclinical and clinical trial 
studies.  Besides the selected Siddha herbal formulation is also studied from chemical and 
botanical standardization point of view in order to contribute to the suffering diabetic 
population a quality standard anti diabetic Siddha herbal drug.  
Following quality standards were determined for Nilavembu Kudineer 
Microscopic standards 
 Wavy epidermal cells  
 Sclerenchyma cells with narrow lumen 
 Vessels with simple pits and scalariform thickening, parenchyma cells with reticulation 
 Tracheids are thick walled 
 Fibres with branching and split ends, libriform, thin walled, with tapering end wide 
lumen  
 Polygonal cork cells 
 Presence of tricolpate pollen grains and group of fibres and brown content, slightly 
elongated and beaker shaped stone cells  
 Presence of unicellular and short and long uniseriate trichomes with bi and tri cellular, 
short and long uniseriate multicellular headed glandular trichome 
 Presence of stone cells and various shaped and striated sclereids 
 Starch grains round to oval calcium oxalate crystals prismatic and acicular  
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8.2 Test for identity, purity and strength 
 pH not more than 7  
 Loss on drying not more than 6%  
 Total ash not more than 31% 
 Acid insoluble ash not more than 2%  
 Alcohol soluble extractives not less than 4%  
 Water soluble extractives not less than 81%  
 
Major chemical constituents 
Alkaloids, sterols, terpenoids, saponins, carbohydrates and mucilage 
 
8.3 HPTLC profiles 
The HPTLC analysis of Nilavembu Kudineer revealed the presence of 11 spots with 
Rf at 0.31, 0.55, 0.58, 0.65, 0.70, 0.77, 0.82, 0.88, 0.92, 0.95 and 0.97 under 254 and 366 nm. 
The Rf value 0.70 indicates the presence of Andrographolide, the marker compound.  
 
8.4 Acute oral toxicity studies 
Data of the results indicated that aqueous extract of Nilavembu Kudineer is non-
toxic, and safe up to 2 g/kg, b. wt. through oral route. 
 
Anti-diabetic activity 
In the present study, STZ induced rats showed significant increase in the level of 
serum urea and creatinine, after treatment with Nilavembu Kudineer in diabetic rats for 28 
days elevated serum urea and creatinine levels were found to be decreased significantly. The 
stabilization of these renal parameters by Nilavembu Kudineer suggests its protection against 
Diabetic nephropathy, which is one of the diabetic complications observed in chronic diabetic 
patients. If used as hypoglycemic agents, may also reverse dyslipedemia associated with 
diabetes and prevent the cardiovascular complications which are very prevalent in diabetic 
patients. 
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8.5 Clinical Studies 
 6 subjects showed vatha naadi, 38 subjects showed pithta naadi and 4 subjects 
showed kapha and thontha naadi.  
 Based on body proportion 22 pitha subjects, 16 kapha subjects and 10 vatha subjects 
were identified. Among this, pitha and kapha people showed marked improvement 
whereas vatha people showed only symptomatic improvement  
 Disorientation of pitha was found in 38 patients out of which 28 recovered. 2 of the 4 
subjects with kapha disorientation, and 3 out of 6 subjects with vatha disorientation 
also recovered to normal. This indicates that this plant was more effective in treating 
pitha dominated diabetic complications as compared to vatha and kapha dominated 
complications.    
 Significant changes in fasting blood sugar were observed only in 28 patients  
 30 subjects showed significant improvement in post prandial glycemic level after 
treatment.  
 Glycated hemoglobin was markedly reduced in 20 patients    
 Most of the subjects reported reduction in excessive appetite, which is the most 
common symptom of Type II Diabetes. 
 
The data of the results obtained clearly depict the anti-diabetic efficacy of Nilavembu 
Kudineer in human subjects.  
 
To conclude the study drug, Nilavembu Kudineer is proved for its quality, both 
botanically and chemically and is found to be safe, effective and economical in the 
management of type 2 Diabetes mellitus and its related complications such as nephropathy. 
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Recommendations 
 It is recommended that Nilavembu Kudineer can be used for adult patients in the 
management of Diabetes mellitus and its complications. 
 This Siddha formulation is also recommended in the cases of Diabetic nephropathy 
due to its potential in stabilizing renal parameters.  
 If Nilavembu Kudineer is used as hypoglycemic agents, may also reverse 
dyslipedemia associated with diabetes and prevent the cardiovascular complications 
which are very prevalent in diabetic patients. 
 Further in depth pharmacodynamic and pharmacokinetics studies are needed to 
understand its bioavailability and release in the biological system. This can contribute 
in understanding the mechanism of anti-diabetic action leading to global acceptance 
and recognition of this unique anti-diabetic Siddha formulation.   
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